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Halesha Dhurvigere Basavarajappa 
The molecular mechanism of action of the antiangiogenic natural product, 
cremastranone 
Prevention of pathological angiogenesis is a key strategy for treatment of 
common blinding ocular diseases such as retinopathy of prematurity, proliferative 
diabetic retinopathy, and wet age-related macular degeneration. The current 
treatment strategies are associated with partial vision loss and are ineffective in a 
significant patient population. Hence novel drugs as well as new ways to target 
ocular angiogenesis are needed for treating these diseases. I pursued a natural 
antiangiogenic compound, cremastranone, to develop novel drug leads and to 
find new targets. The objective of my doctoral thesis project was to elucidate 
cremastranone’s molecular mechanism of action and optimize its structure-
activity relationship (SAR). 
In order to achieve this goal, with the help of chemistry collaborators 
cremastranone was synthesized for the first time. I showed that cremastranone 
has 50-fold more potency against endothelial cells as compared to non-
endothelial cells, and also tested a novel active isomer, SH-11052. By SAR 
studies I identified a potent molecule, SH-11037, that has 10-fold more selectivity 
against retinal endothelial cells as compared to macrovascular endothelial cells. I 
then elucidated cremastranone’s molecular mechanism using a chemical 
proteomic approach. I identified ferrochelatase (FECH) as a specific interacting 
protein partner of cremastranone using photoaffinity chromatography. Hence, I 
		 vii 
hypothesized that cremastranone exerts its antiangiogenic activities through 
modulation of the functions of FECH. 
Cremastranone inhibited the enzymatic activity FECH in endothelial cells. 
Therefore, I investigated the role of FECH in ocular angiogenesis. Partial loss of 
FECH, using a siRNA-based knock down approach, decreased retinal 
angiogenesis both in vitro and in vivo in mouse models. Knock down of FECH 
decreased the expression levels of key proangiogenic proteins HIF-1α, eNOS, 
and VEGFR2. This work suggests that ferrochelatase plays an important, 
previously undocumented role in angiogenesis and that targeting of this enzyme 
by cremastranone might be exploited to inhibit pathological angiogenesis in 
ocular diseases. 
Timothy W. Corson, Ph.D., Chair 
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CHAPTER 1. INTRODUCTION 
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1.1 CHAPTER SUMMARY 
In this introductory chapter an overview of angiogenesis and its molecular 
mechanism with special emphasis on pathological angiogenesis in the eye is 
discussed. Formation of new blood vessels in the eye (also called ocular 
neovascularization) underlies numerous diseases such as retinopathy of 
prematurity (ROP) in infants, proliferative diabetic retinopathy (PDR) in adults 
and wet age-related macular degeneration (wet AMD) in elderly people. These 
ocular diseases arising from pathological angiogenesis and current treatments 
including the development of new therapies are explained in detail. Further, as a 
part of discovering novel drugs for treating ocular diseases arising from ocular 
angiogenesis, natural products with special emphasis on homoisoflavanones are 
discussed. Towards the end of the chapter an antiangiogenic homoisoflavanoid, 
cremastranone is emphasized along with the context and rationale for my 
dissertation work. The overall goal of this study is to improve the knowledge on 
novel ways to inhibit ocular angiogenesis and thereby pave the way for 
discovering new and effective therapies for ocular diseases. 
1.2 OVERVIEW OF ANGIOGENESIS 
 Vertebrates have developed an elaborate network of blood vessels to 
nourish all the organs of the body. This network enables every cell of the body to 
get enough oxygen and nutrients along with the waste disposal system. In 
addition cells of the immune system patrol for immune surveillance through this 
network. As blood vessels nourish every organ of the body, deviation from the 
normal pattern of vessel growth contributes to numerous diseases. Insufficient 
		 3 
blood vessel formation leads to stroke, myocardial infarction, ulcerative disorders 
and neurodegeneration. Excessive or abnormal blood vessel formation is 
associated with cancer, inflammatory disorders, pulmonary hypertension and 
blinding eye diseases such as retinopathy of prematurity (ROP), diabetic 
retinopathy (DR) and wet-age related macular degeneration (Alitalo and 
Carmeliet, 2002; Carmeliet, 2003; Carmeliet and Jain, 2011). These ocular 
diseases will be discussed further, below. Before getting into the details of the 
molecular events of blood vessel formation it is imperative to understand the 
cellular composition and organization of blood vessels. 
1.2.1  Histology of blood vessels 
Blood vessels are composed of endothelial cells, perivascular cells and 
extracellular matrix (including collagen and elastin) organized into three layers – 
Tunica intima, Tunica media and Tunica adventitia. 
1.2.1A. Tunica intima (tunica intern): It is the thinnest layer facing the 
lumen of the blood vessel. It is composed of a single layer of endothelial cells 
and is separated from tunica media by a dense elastic lamina (also called basal 
lamina). 
1.2.1B. Tunica media: It is the thickest layer and provides structural 
support, vasoreactivity and elasticity to blood vessels. It is composed of 
perivascular cells, elastic fibers and connective tissue.  Perivascular cells, 
general term used for cells enveloping the blood vessels, are contractile cells and 
referred to as vascular smooth muscle cells (vSMCs), pericytes (PCs) or mural 
		 4 
cells based on the type of blood vessels – in large blood vessels such as 
arteries, veins and arterioles they are called vascular smooth-muscle cells and in 
small blood vessels such as capillaries and venules they are termed as pericytes  
(Hughes and Chan-Ling, 2004). Thickness of tunica media depends on size of 
the blood vessels. While small blood vessels contain scarcely distributed 
pericytes, large blood vessels contain multiple layers of vascular smooth-muscle 
cells, elastic and collagen fibers. Perivascular cells maintain communications 
with endothelial cells through both physical contact and paracrine signaling. They 
play crucial roles in regulating the flow of blood by contracting and relaxing the 
blood vessels. Perivascular cells are also required for maturation of vasculature 
and loss of these cells results in regression of blood vessels as observed in 
ocular complications such as macular edema and diabetic retinopathy 
(Carmeliet, 2000).  
1.2.1C. Tunica adventitia (Tunica externa): It is mainly made up of 
connective tissue, nutrient vessels (called vasa vasorum), autonomous nerves 
(nervi vasorum) fibroblasts and macrophages. 
While all the above three layers are present in larger blood vessels, tunica 
media and tunica adventitia are absent in capillaries. Capillaries are made up of 
a single layer of endothelial cells surrounded by basal lamina, in which are 
embedded pericytes. 
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1.2.2   Formation of blood vessels 
Cells required for the formation of blood vessels originate from the 
mesodermal layer of the embryo. During embryonic development, new blood 
vessels are formed by the differentiation of endothelial precursor cells (called 
‘angioblasts’) into endothelial cells. These differentiated endothelial cells then 
assemble into a primitive vascular labyrinth. This process is called 
vasculogenesis (Swift and Weinstein, 2009). Further formation of new blood 
vessels from vascular labyrinth occurs through a process called ‘angiogenesis’.  
Angiogenesis is a process of formation of new blood vessels from 
preexisting ones (Carmeliet and Jain, 2011). Angiogenesis during embryonic 
development creates a network that remodels into arteries and veins. Later 
pericytes and vSMCs are recruited to nascent blood vessels to provide stability 
and to regulate perfusion. In adults, blood vessels are quiescent and rarely form 
new branches. However, endothelial cells (ECs) retain high plasticity to sense 
and respond to angiogenic signals to form new vessels (Potente et al., 2011). 
Earlier it was believed that vasculogenesis occurs only during embryonic 
development, however later reports indicate occurrence of vasculogenesis in 
adults by endothelial progenitor cells (EPCs) circulating in the blood (Asahara et 
al., 1997; Grant et al., 2002; Shi et al., 1998). However, angiogenesis remains 
the major pathway of new blood vessel formation in adults. As the major goal of 
this study is based on angiogenic process, in the following sections 
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vasculogenesis is briefly described whereas the cellular and molecular events of 
angiogenesis are described in detail. 
1.2.3. Vasculogenesis 
ECs and hematopoietic cells have common progenitor cells called 
‘hemangioblasts’. During embryonic development, in the yolk sac, 
hemangioblasts aggregate. The inner cells develop into hematopoietic precursor 
cells and the outer population into angioblasts (Figure 1.1). Angioblasts 
proliferate and migrate extensively before de novo differentiation into endothelial 
cells and formation of vascular labyrinth (Potente et al., 2011). The differentiation 
of angioblasts into ECs is influenced by basic fibroblast growth factor (bFGF), 
vascular endothelial growth factor (VEGF), and VEGF receptor 2 (VEGFR2) 
(Carmeliet et al., 1996; Ferrara, 1999; Ferrara et al., 1996; Shalaby et al., 1997). 
This vascular labyrinth then undergoes stabilization and maturation by the 
recruitment and enwrapping of pericytes around the vessels. Pericytes are 
derived from mesenchymal stem cells or neural crest cells and the recruitment 
takes place through chemotaxis process wherein ECs secrete platelet derived 
growth factor –B (PDGF-B) and pericytes expressing PDGF-B receptors are 
attracted to the vessel formation site (Bergers and Song, 2005; Hellstrom et al., 
1999). The vascular labyrinth then remodels into an organized network of 
arteries, capillaries and veins. Notch signaling plays a key role in deciding the 
fate of ECs to become arteries or veins. Notch pathway components are highly 
expressed in arteries whereas venous ECs express low levels of Notch 
components (Gridley, 2010; Potente et al., 2011; Swift and Weinstein, 2009). 
		 7 
 
Figure 1.1. Pictorial representation of vasculogenesis and angiogenesis. 
Reproduced with permission from Oxford University Press (Bergers and Song, 
2005). 
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1.2.4. Angiogenesis 
Angiogenesis is a tightly controlled process guided by a set of pro-
angiogenic and antiangiogenic molecules.  Angiogenesis occurs during growth, 
wound repair and reproduction (ovulation, follicular development, implantation 
and placentation during pregnancy) (Tahergorabi and Khazaei, 2012).   
Although angiogenesis can occur through intussusception (splitting of pre-
existing vessels), under physiological conditions angiogenesis occurs through a 
process called sprouting. The key molecular events during sprouting were 
identified using mouse retina wherein the development of vasculature occurs 
postnatally (Welti et al., 2013). Sprouting angiogenesis takes place in the 
following steps: 
• Vasodilation and increased vascular permeability 
• Tip and stalk cell selection 
• Endothelial cell proliferation and migration 
• Vessel branch fusion 
• Vessel maturation, stabilization and quiescence 
		 9 
1.2.4A. Vasodilation and increased vascular permeability: The 
sprouting process begins with vasodilation, a process involving nitric oxide. 
VEGF increases vascular permeability in order to allow extravasation of plasma 
proteins that lay down a scaffold for migrating ECs.  
In order for ECs to emigrate from their resident site, they need to loosen 
cell-cell contacts between them and with pericytes. In other words, mature 
vessels need to be destabilized. This occurs by the detachment of pericytes from 
blood vessels promoted by angiopoietin 2 (Ang2), an inhibitor of Tie2 signaling, 
released from ECs (Welti et al., 2013). This is followed by degradation of 
basement membrane by matrix metalloproteinases (MMPs) such as MMP1 
secreted by ECs. These MMPs also liberate proangiogenic growth factors that 
are sequestered in the matrix. During this process antiangiogenic molecules such 
as plasminogen activator inhibitor are also released to prevent abnormal 
sprouting and to coordinate branching of vessels (Potente et al., 2011; Welti et 
al., 2013). 
1.2.4B. Tip and stalk cell selection: Attracted by proangiogenic signals, 
ECs become motile, invasive and protrude filopodia. These ECs are called ‘Tip 
cells’. These tip cells spearhead new sprouts and probe the surrounding 
environment for guidance cues. Tip cells then play a master role in formation of 
the vessel. Tip cells dissociate from the capillary and move towards the 
proangiogenic signal gradient. Then, the surrounding endothelial cells, called 
“stalk cells”, proliferate and migrate along with tip cells. The specification of ECs 
into tip and stalk cells is controlled by the Notch pathway. Stalk cells exhibit 
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higher Notch activity as compared to tip cells. Blockade of Notch signaling is 
observed in tip cells that express higher levels of DLL4 ligand (Carmeliet, 2000; 
Potente et al., 2011; Welti et al., 2013).  
VEGF/VEGFR2 enhances DLL4 expression in tip cells. DLL4-mediated 
activation of Notch in neighboring ECs inhibits tip cell behavior in these cells by 
downregulating VEGFR2, VEGFR3 and neuropilin 1 (NRP1), a co-receptor of 
VEGFR2. Following exposure to VEGF, all ECs upregulate DLL4. However, ECs 
that express DLL4 more quickly or at higher levels have a competitive advantage 
to become tip cells as they activate Notch signaling in neighboring cells more 
effectively. Hence ECs at the angiogenic front dynamically compete for the tip 
position through DLL4/Notch signaling (Potente et al., 2011; Welti et al., 2013). 
1.2.4C. Endothelial cell proliferation and migration: Compared to tip 
cells, stalk cells have fewer filopodia and they are more proliferative. Stalk cells 
have the ability to form tubes and branches. VEGF/VEGFR2 signaling is the key 
driver for proliferation and migration of ECs. Along with VEGF, other growth 
factors such as Insulin-like growth factor (IGF-1), placental growth factor (PLGF), 
bFGF, PDGF, TGF-β1, TNF-α and αvβ3 integrin also promote proliferation and 
migration of ECs (Carmeliet, 2000; Potente et al., 2011). 
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1.2.4D. Vessel branch fusion: When two tip cells from opposite branches 
of capillaries meet then they fuse to become tubes. Once the contact between tip 
cells is established, VE-cadherin-containing junctions are formed between ECs to 
consolidate the connection.  
1.2.4E. Vessel maturation, stabilization and quiescence: Maturation of 
newly formed blood vessel takes place wherein proliferation and migration of 
endothelial cells are halted, pericytes and vascular smooth muscle cells are 
recruited and basement membrane for blood vessels is laid out. Recruitment of 
pericytes to newly formed vessels is controlled by PDGF/PDGF-B signaling. ECs 
secrete PDGF-B and pericytes, which express receptors for PDGF-B, are 
attracted to the site of the newly formed blood vessel (Carmeliet and Jain, 2011; 
Tahergorabi and Khazaei, 2012; Welti et al., 2013). In turn, pericytes produce 
Ang1, which activates Tie2 signaling in ECs to promote pericyte adhesion to ECs 
and tightening of endothelial junctions. Once the vessel is matured the blood 
flows through newly formed vessels. This exposure to oxygenated blood 
suppresses hypoxia-inducible factors (HIFs) in ECs and proliferative activity is 
decreased. As endothelial proliferation decreases during maturation, ECs adopt 
survival properties to maintain integrity of the vessel lining. Autocrine and 
paracrine survival signals from endothelial and support cells protect the vessel 
from environmental stresses. VEGF is the main survival factor for ECs through 
the activation of the PI3K/AKT pathway (Potente et al., 2011; Welti et al., 2013). 
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Until now, I have briefly discussed key cellular events of angiogenesis with 
mention of key signaling pathways in each of the step. In the following section, 
key molecular players of angiogenesis are discussed. 
1.3. MOLECULAR MECHANISM OF ANGIOGENESIS 
The main trigger for initiation of angiogenesis is hypoxia (Das and 
McGuire, 2003). Under low oxygen concentration, hypoxia Inducible factor-1 
(HIF-1) is stabilized in endothelial cells (ECs). This stabilized transcription factor 
HIF-1 then upregulates expression of many proangiogenic molecules including 
vascular endothelial growth factor (VEGF), angiopoietin-2 (ang-2) and fibroblast 
growth factor (FGF) (Das and McGuire, 2003). Apart from this Notch, Tie2 and 
PDGF signaling play important roles in angiogenesis (Papetti and Herman, 
2002). In the following sections each of these are described. 
1.3.1 Vascular Endothelial Growth Factor (VEGF) 
Among all the proangiogenic molecules, VEGF is the most potent one  
(Penn et al., 2008). VEGF is essential for angiogenesis and a lack of a single 
allele arrests angiogenesis and leads to embryonic lethality (Ferrara et al., 1996). 
VEGF is a dimeric glycoprotein of approximately 40 kDa size. In mammals, the 
VEGF family consists of seven members: VEGF-A (typically referred as VEGF), 
VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and placental growth factor 
(PlGF). Among these members, VEGF-A is the potent inducer of angiogenesis. 
The VEGFA transcript undergoes alternate splicing to produce several variants 
with different functions. These variants are VEGF121, VEGF145, VEGF165, 
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VEGF189 and VEGF206. These variants differ in their ability to bind heparin. 
VEGF189 and VEGF206 have high heparin binding capacity and are hence 
sequestered in ECM while VEGF121 lacks heparin binding ability and hence are 
highly soluble. VEGF165 and VEGF145 have less affinity for heparin but are 
associated with ECM. Among all the VEGF variants VEGF165 is the predominant 
one (Penn et al., 2008).  
The expression of VEGF is mainly induced by hypoxia (Carmeliet et al., 
1998; Penn et al., 2008). HIF-1 is the key transcriptional factor, which under 
hypoxic conditions binds to the hypoxia responsive element (HRE) of the VEGF 
promoter and upregulates the production of VEGF mRNA. Apart from this, under 
hypoxia stability of VEGF mRNA is also increased 2-3 fold due to binding of HuR, 
a 36-kDa RNA-binding protein, to the 3’ UTR of VEGF mRNA, protecting it from 
degradation from endonucleases (Brennan and Steitz, 2001). 
1.3.2. VEGF receptors 
VEGF receptors are tyrosine kinase family receptors in the membrane 
with seven immunoglobulin-like folds on the extracellular side of the protein, a 
single transmembrane region and a tyrosine kinase domain at the intracellular 
region of the protein. VEGF receptors contain three members; VEGFR-1/Flt-1, 
VEGFR-2/KDR/Flk-1 and VEGFR-3/Flt-4. VEGFR-1 and -2 are mainly involved in 
angiogenesis whereas VEGFR-3 is involved in lymphangiogenesis (Yancopoulos 
et al., 2000). VEGF165 induces its angiogenic potential through binding to 
VEGFR-2 (Penn et al., 2008). Once activated, VEGFR-2 recruits a host of 
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different signaling proteins involved in proliferation, migration and survival of 
endothelial cells as depicted in Figure 1.2. Hypoxia does not directly upregulate 
VEGFR-2 expression. However VEGF, which is induced by hypoxia, potentiates 
the expression of VEGFR-2. 
 
 
 
Figure 1.2. VEGF receptor and its signaling pathways. 
1.3.3. VEGF/VEGFR-2 signaling 
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phosphorylated VEGFR-2, PI3K protein binds and activates AKT as well as 
p38MAPK pathway to promote both survival and migration of ECs respectively 
(Figure1.2) (Penn et al., 2008). 
1.3.4. Basic fibroblast growth factor (bFGF) 
FGFs are 18-25 kDa polypeptides and ubiquitously expressed. bFGF 
plays an important role in angiogenesis in vitro. bFGF strongly promotes 
proliferation, migration and tube formation ability of ECs in vitro. bFGF binds to 
heparin with high affinity and hence is sequestered in ECM. FGFs have been 
implicated in retinal neovascularization (Das and McGuire, 2003). However the 
role of bFGF in vivo seems to be redundant as mice lacking bFGF show normal 
vasculature (Tobe et al., 1998). Thus there is contradictory findings regarding the 
role of bFGF in ocular neovascularization wherein one school of researchers 
believe bFGF induces angiogenesis (Hanneken et al., 1991; Kimura et al., 1999; 
Sivalingam et al., 1990) while the other group believe bFGF plays little role in 
angiogenesis in vivo (Ozaki et al., 1998; Tobe et al., 1998). 
1.3.5. Platelet derived growth factor (PDGF) 
In order to avoid the regression of newly formed blood vessels, pericytes 
need to be recruited. This recruitment of pericytes to neovascularized areas is 
promoted by PDGF-B secreted by ECs. Loss of pericytes is a hallmark of 
diabetic retinopathy and a strong correlation between reduced pericyte density 
and low PDGF levels has been demonstrated in mice (Bergers and Song, 2005; 
Carmeliet, 2000). 
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1.3.6. Notch signaling 
During the initiation of angiogenesis some ECs are destined to become 
“tip cells”. Selection of tip cells takes place through Notch signaling (Welti et al., 
2013). ECs after activation by VEGF, compete for tip position by increasing the 
expression of the Notch ligand Delta-like 4 (DLL4), which binds to Notch 
receptors on adjacent ECs (stalk cells). Activated Notch receptors undergo 
protein cleavage and release Notch intracellular domain (NICD), which acts as a 
transcriptional regulator decreasing the expression of VEGFR2 and NRP-1 
(neuropilin-1, coreceptor of VEGFR-2) while increasing the expression of 
VEGFR-1, which traps VEGF. Thus Notch signaling distinguishes ECs as tip 
cells and stalk cells. However, it is VEGF signaling that promotes proliferation, 
migration and tube formation abilities of ECs. Once the tip cells from opposing 
sides of the capillary fuse and form a nascent blood vessel, maturation and 
stabilization of the blood vessel takes place through recruitment of pericytes 
(Potente et al., 2011; Welti et al., 2013).  
Mural pericytes reduce EC proliferation, migration and vessel leakage. 
TGF-β1 promotes differentiation of precursor cells to pericytes and ECs secreting 
PDGF-B attract pericytes expressing PDGFR-β. Once the hypoxic tissue is 
perfused, ECs go into quiescence. Ang-1 signaling in ECs inhibits the 
permeability of new blood vessels by inducing DLL4 expression and NICD 
signaling. Basement membrane is laid around quiescent ECs to promote vessel 
stabilization.  
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Apart from the above described signaling pathways there are many new 
signaling pathways being linked to angiogenesis but their role in ocular 
angiogenesis is not clearly understood. In the following section, some of the 
ocular diseases arising from uncontrolled angiogenesis are discussed. 
1.4. OCULAR DISEASES ARISING FROM PATHOLOGICAL 
ANGIOGENESIS 
Pathological angiogenesis in the eye leads to several ocular diseases, 
including three prevalent ones: ROP, PDR and wet AMD. These three diseases 
together are a leading cause of vision loss in the world (Penn et al., 2008). 
Pathological angiogenesis links these ocular diseases. In order to understand the 
pathologies of these diseases, anatomy and histology of the human eye is briefly 
discussed below. 
1.4.1   Anatomy of the human eye 
The human eye is a fluid-filled sphere enclosed by three layers of tissues  
• Outer layer – this is composed of tough white fibrous tissue called 
‘sclera’. However, at the front of the eye this layer is transparent and 
the region is called ‘cornea’. The cornea permits the light rays into 
the eye. 
• Middle layer – this layer includes three distinct but continuous 
structures: The iris, the ciliary body and the choroid. The iris is the 
colored portion of the eye and controls the amount of light to be 
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entered into the eye. The choroid is composed of a rich capillary bed 
that serves as the main source of blood supply for the photoreceptors 
of the retina. 
• Inner layer – this layer, the retina, includes photoreceptors that are 
sensitive to light and neurons/glia that are capable of transmitting the 
visual signals to brain.  
1.4.2  Retinopathy of prematurity 
ROP arises from perturbation in the normal vascular development of retina  
(Sapieha et al., 2010). Retina is one of the last organs to be vascularized in the 
human fetus. ROP occurs in two distinct phases: the first phase is associated 
with inhibition of normal retinal vasculature due to exposure of the premature 
baby to hyperoxia environment (oxygen therapy). In this phase VEGF levels are 
decreased. The second phase is associated with rapid growth of abnormal leaky 
blood vessels into the vitreous, followed by vitreous hemorrhage and retinal 
detachment.  This phase occurs due to transfer of the premature baby from 
hyperoxia to normoxia. This causes a relative hypoxic environment in the eye 
leading to triggering of upregulation of VEGF (Penn et al., 2008). The two distinct 
phases of this disease makes the treatment more complicated, as angiogenesis 
needs to be promoted in the first phase and inhibited in the second phase.  
In the United States, 70% of the infants with very low birth weight develop 
ROP after exposure to postnatal hyperoxia. Around 1,300 infants per year in the 
United States develop complete vision loss due to this disease, and 500 more 
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are severely impaired (Faia and Trese, 2011). Overall, between 6% and 18% of 
childhood blindness is attributable to ROP (Gilbert et al., 1997). Moreover, as 
more and more children survive premature birth in middle-income countries due 
to improvements in neonatal intensive care, ROP is becoming more prevalent 
worldwide. The traditional therapies for ROP are laser photocoagulation, 
cryotherapy and surgical interventions. However the main drawbacks of these 
therapies are that they are all invasive therapies with partial loss of peripheral 
vision. 
1.4.3 Diabetic retinopathy (DR) 
Similar to ROP, in adults due to diabetic complications (because of high 
blood glucose levels) there is initially regression of retinal vasculature followed by 
abnormal growth of blood vessels in the retina. DR is the most common 
complication in diabetes and clinical symptoms of DR are seen in 75% of diabetic 
patients, with 10% of them eventually developing visual impairment (Penn et al., 
2008). DR is currently the leading cause of blindness among working age adults 
and accounts for 8% of the legal blindness in the United States (Penn et al., 
2008). Clinical progression of DR includes adhesion of leukocytes to the vessel 
wall (leukostasis), aggregation of platelets, altered blood flow, degeneration of 
pericytes and thickening of basement membranes. Blockage of retinal capillaries 
then causes localized hypoxia triggering increased production of angiogenic 
factors, mainly VEGF. Despite increased production of VEGF, a potent survival 
factor for ECs, microvascular retinal ECs degenerate, leading to capillary closure 
and formation of acellular non-perfused capillaries. With the disease progression, 
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vascular leakage increases and blood and fluid accumulate in the retinal tissue 
forming exudative deposits, a condition called non-proliferative diabetic 
retinopathy (NPDR).  
In some patients NPDR progresses to proliferative diabetic retinopathy 
(PDR). PDR is characterized by new blood vessel formation on the surface of the 
retina, analogous to that seen in the second phase of ROP. These new blood 
vessels are fragile and may break, leaking blood into the vitreous thus clouding 
the vitreous and compromising vision. In advanced PDR fibrovascular scar tissue 
grows from the retinal surface into the vitreous cavity. If left untreated, this can 
cause retinal detachment and hence blindness (Penn et al., 2008). The specific 
reasons for disease progression and retinal injury in diabetic patients are not yet 
clear. But there is strong support for the concept that elevation of blood and 
tissue glucose levels stimulates production of proangiogenic factors, mainly 
VEGF, and upregulates VEGFR2 (Gilbert et al., 1998; Miller et al., 1997). High 
glucose, oxidative stress, hypoxia and inflammatory reactions occur in diabetes 
and all of these conditions are shown to promote the expression of VEGF. Hence 
blocking the action of VEGF might prevent PDR. The current treatment methods 
for PDR are laser therapy and administration of anti-VEGF biologics. While laser 
therapy is effective in many patients, the loss of retinal tissue during the process 
can lead to decreased peripheral vision, impair night vision and change color 
perception (Penn et al., 2008). Administration of anti-VEGF biologic drugs blocks 
the progression of PDR. The available anti-VEGF drugs for treatment are Avastin 
(bevacizumab), Lucentis (ranibizumab) and Eylea (aflibercept). Lucentis and 
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Eylea are approved by FDA for treatment of PDR while Avastin is approved for 
treating cancer but is commonly used in clinics to treat PDR.  
1.4.4  Age-related Macular degeneration 
Unlike ROP and PDR, which are caused by retinal neovascularization, 
AMD is associated with choroidal neovascularization. Age-related macular 
degeneration is one of the leading causes of vision loss worldwide (Resnikoff et 
al., 2004).  AMD develops late in life and both genetic and environmental factors 
play key roles in pathogenesis. AMD can be categorized into dry and wet AMD 
forms. Dry AMD is a chronic disease caused by slow photoreceptor degeneration 
and nearly 90 % of AMD patients belong to this category. There is no treatment 
for these patients. However NIH clinical studies (age-related eye disease studies 
–AREDS) indicated that a combination of vitamins C, E, beta-carotene, zinc and 
copper can reduce the risk of progression by 25 %. Wet AMD affects 
approximately 2 million people in the United States and is estimated to engender 
a productivity burden of nearly $5.4 billion (Fine et al., 2000). Although less 
common than dry AMD, wet AMD is responsible for causing approximately 90 % 
of the legal blindness associated with this disease (Fine et al., 2000). Wet AMD 
is characterized by pathogenic neovascularization of the choroid, projecting 
through Bruch’s membrane and into the adjacent retinal pigment epithelium. 
Rupture of these new blood vessels causes hemorrhage, rapid photoreceptor 
degeneration and eventual fibrotic scarring, with rapid vision loss (Ehrlich et al., 
2009). Established treatment modalities for wet AMD include photodynamic 
therapy, laser surgery and administration of anti-VEGF biologics. The most 
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common therapy for wet AMD patients is anti-VEGF drugs and photodynamic 
therapy is less commonly used, in conjunction with anti-VEGF therapy.  
1.4.5  Anti-VEGF biologic drugs 
Anti-VEGF biologic drugs work by interfering in VEGF binding to VEGF 
receptors and thereby blocking VEGF-VEGFR2 signaling. Currently there are 
three anti-VEGF drugs licensed for use in eye diseases – pegaptanib (brand 
name – Macugen), aflibercept (brand name – Eylea), ranibizumab (brand name – 
Lucentis) and one that is not licensed but used off-label – bevacizumab (brand 
name – Avastin). Pegaptanib, an aptamer, is a selective inhibitor of VEGF165 
and was the first anti-VEGF agent approved for eye diseases in 2004 
(Gragoudas  et al., 2004). This was followed in 2006 by ranibizumab, a 
monoclonal antibody (Rosenfeld  et al., 2006) and in 2011 by aflibercept, a fusion 
protein containing VEGF-binding regions of VEGF receptors 1 & 2 fused to Fc 
portion of human IgG1 immunoglobulin (Heier et al., 2012). Off-label use of 
bevacizumab is robust since 2005 and it maintains the predominant market share 
due to similar efficacy to ranibizumab with a distinct pricing advantage (Avery et 
al., 2006).    
 However these medications face an unfavorable cost to benefit ratio 
(Hodge et al., 2010; Mitchell et al., 2011) and have the potential for significant 
acute systemic side effects such as non-ocular hemorrhage and myocardial 
infarction (Folk and Stone, 2010b). There is also a significant population that is 
refractory to these drugs; up to 45% in one series of AMD patients (Lux et al., 
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2007). Hence targeting not only VEGF signaling but multiple proangiogenic 
signals is required to improve the efficacy of treatment for diseases arising from 
pathological angiogenesis. Thus, there is a critical unmet medical need to 
develop novel therapies to either replace or supplement the present therapies to 
increase the efficiency of treatment of these diseases. At present there is no 
small molecule drug to treat these ocular diseases on the market, although many 
investigational small molecule inhibitors of angiogenesis (such as TG10080, 
PTK787, PAN90806 and squalamine) are in various stages of clinical trials 
(Englander and Kaiser, 2013). Towards this end, our long-term goal is to identify 
and develop novel small molecules that not only inhibit angiogenesis in the eye 
but also might be delivered topically rather than by injection which is the main 
delivery route for all of the biologics (Folk and Stone, 2010). 
1.5 NATURAL PRODUCTS AS INHIBITORS OF OCULAR ANGIOGENESIS  
The medicinal use of natural products obtained from plants and animals 
dates back thousands of years (Ji et al., 2009). Different human civilizations 
across the world used these natural products as treatment for a majority of the 
diseases, wherein extracts of plants were either taken orally or applied topically. 
However only during the 19th century a systematic study of extracting active 
ingredients from these natural extracts were carried out, mainly because of 
advancements in analytical and structural chemistry. The discovery of the 
antibiotic penicillin revolutionized the medicinal chemistry field to identify active 
chemical compounds from natural products. As the technology for identifying and 
determining the structure of compounds became available there was an 
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explosion of drug discovery research based on natural products (Ji et al., 2009; 
Newman et al., 2003). In the 20th century more than 50 % of the approved drugs 
are either natural products or their derivatives such as antibiotics, 
immunosuppressants and anticancer drugs, which have revolutionized human 
medical history and improved the quality of life (Li and Vederas, 2009). The 
discovery and development of antibiotics not only saved millions of lives but also 
set the platform for big pharmaceutical companies to explore the field to develop 
drugs based on natural products for other diseases. One of the main reasons to 
investigate natural products is that over millions of years nature has perfected the  
interaction between natural product and its interacting partner (drug target). So 
understanding these interactions further gives us an avenue for exploring novel 
chemicals through rational design of drugs in target based drug discovery 
programs (Schmidt et al., 2007). As natural products offer specificity as well as 
chemical diversity they serve as lead molecules in drug discovery.  
Despite these advantages, there was a decline in natural products-based 
drug discovery programs as there were technological revolutions in molecular 
biology, synthetic and computational chemistry, which made it easier to rationally 
design new synthetic drugs based on drug target structure.  However in the past 
few years there is renewed interest in the use of natural products as a basis of 
drug development. This is partly because several natural products have 
undergone clinical evaluation and shown promising results especially in cancer, 
immunological and inflammatory diseases (Mishra and Tiwari, 2011). Interest in 
natural products will continue as advances in bioprospecting, separation and 
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structure determination technologies ensure natural products with more chemical 
diversity and hence novel chemical templates to synthesize new chemicals with 
intellectual patent (IP) properties. Natural sources may also provide lead 
molecules with favorable absorption, distribution, metabolism, excretion and 
toxicity (ADMET) characteristics (Corson and Crews, 2007; Koehn and Carter, 
2005).  
Several natural products have been tested for their antiangiogenic 
properties in context with cancer. However very few have been tested for their 
efficacy in ocular diseases (Sagar et al., 2006a, b). These tested natural products 
are chemically diverse and have promising effects.  
Of these molecules polyphenols are of interest as they are abundant in 
nature and are constituents in many medicinal plants. They are recognized for 
their antioxidant properties and hence tested in animal models of diseases 
associated with oxidative stress such as cancer, inflammatory diseases and 
cardiovascular diseases (Manach et al., 2004). Polyphenols is a general term 
used to describe aromatic compounds containing several hydroxyl groups. Based 
on number of phenolic groups and arrangement of aromatic rings they are 
classified as phenolic acids, flavonoids, stilbenoids and lignans. Of particular 
interest are flavonoids as these have been studied for their beneficial role in 
ocular diseases (Majumdar and Srirangam, 2010; Manach et al., 2004). 
Flavonoids are further classified based on substitution on the heterocycle ring, 
position and length of the linker connecting cycle moieties. One of the flavonoids 
of interest to us is a homoisoflavanone, and is described in the following section. 
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1.6. CREMASTRANONE 
The extract from the bulb of a plant Cremastra appendiculata is used in 
East Asia to treat several cancers and skin lesions. A South Korean research 
group isolated an active compound from this extract and gave it the generic 
name “homoisoflavanone” (Shim et al., 2004) (Figure 2.1). This compound, 5,7-
dihydroxy-3(3-hydroxy-4-methoxybenzyl)-6-methoxychroman-4-one, is a member 
of a small group of known homoisoflavanones; we named it cremastranone. 
Shim et al. identified cremastranone as the component of C. appendiculata bulbs 
responsible for a blockade of the proliferation of human umbilical vein endothelial 
cells (HUVECs) (Shim et al., 2004). This potent compound also inhibits vascular 
tube formation and migration induced by basic fibroblast growth factor (bFGF) in 
tissue culture, without marked cytotoxicity (Kim et al., 2007; Shim et al., 2004). 
Further it was shown that the compound inhibits angiogenesis in vivo. 
Cremastranone showed efficacy in the laser photocoagulation murine model of 
choroidal neovascularization: here, cremastranone inhibited choroidal 
neovascularization (Kim et al., 2008). This model is widely used for testing the 
efficacy of drugs used for wet AMD. Cremastranone was also efficacious in an 
oxygen-induced retinopathy mouse model, a widely used model to understand 
the ROP disease, suggesting it inhibits retinal neovascularization (Kim et al., 
2007). Reassuringly, injection of 10 µM cremastranone into the vitreous of 
normal adult mice showed no cytotoxic or inflammatory effects on the retina, nor 
did it induce apoptosis of retinal cells (Kim et al., 2008). 
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1.7. SUMMARY, HYPOTHESIS AND SPECIFIC AIMS 
In summary, blood vessels are formed through both vasculogenesis and 
angiogenesis during embryonic growth and in adults angiogenesis is the major 
route for new blood vessel formation. Although angiogenesis does not take place 
under normal physiological conditions except during wound repair and 
reproduction, under certain disease conditions such ROP, PDR and wet AMD 
abnormal blood vessel formation occurs. To treat these diseases various 
antiangiogenic therapies have been employed and the most dominant drugs in 
the market are anti-VEGF biologic drugs. Although a few small molecule 
inhibitors of angiogenesis are being tested in both preclinical and clinical settings, 
the progress is limited. Hence there is a need to discover new drugs with less 
toxicity, high potency and specificity. Cremastranone is a candidate molecule 
with antiangiogenic effects in vitro and in vivo.  
Given these impressive findings, our long term goal is to develop an 
understanding of how cremastranone acts as an antiangiogenic agent relevant to 
treating ocular diseases arising from pathological angiogenesis. In order to 
understand the molecular mechanism of cremastranone, I hypothesized that 
cremastranone binds to and modulates the activity of cellular proteins required 
for ocular angiogenesis. To address this hypothesis I designed three specific 
aims: 
Specific Aim 1: To synthesize and biologically characterize 
cremastranone, its analogues and affinity reagents. This step is important to 
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understand if synthetic cremastranone has similar biological properties to its 
natural counterpart and helps in synthesizing enough quantities for use in 
mechanistic studies. Also this step is required for synthesizing affinity reagents 
for use in photo-affinity based pull down assay (Chapters 2, 3, and 4). 
Specific Aim 2: To identify and validate cremastranone interacting 
proteins. This step helps in identifying the proteins with which cremastranone 
interacts and also testing if it is through these proteins that cremastranone exerts 
its antiangiogenic activity (Chapter 5). 
Specific Aim 3: To understand the role of cremastranone binding proteins 
in ocular angiogenesis. This step helps us in knowing if the cremastranone 
binding protein(s) are required for ocular angiogenesis in vivo and also the 
molecular mechanisms through which the target protein(s) are involved in 
angiogenesis (Chapter 5). 
This study proceeded as follows: our South Korean synthetic chemist 
collaborators synthesized cremastranone and an isomer of it. After assessing the 
biological functions of these compounds (Chapters 2 and 3) to be very similar to 
that of homoisoflavanones extracted from natural source, we set out to elucidate 
the structure-activity relationship studies of cremastranone to understand how to 
improve the potency of this compound and where to add chemical linker groups 
to synthesize a photoaffinity reagent.  During this process I came across a potent 
homoisoflavonoid, which is very specific against retinal microvascular endothelial 
cells and inhibited retinal neovascularization in vivo (Chapter 4). Using the 
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photoaffinity chemical reagent synthesized, I was able to identify that 
cremastranone binds and modulates the activity of ferrochelatase, a heme 
synthesizing enzyme (Chapter 5). The functional roles of ferrochelatase and 
heme biosynthesis in reference to angiogenesis are further discussed in 
Chapters 5 and 6. 
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CHAPTER 2. SYNTHESIS AND MECHANISTIC STUDIES OF A NOVEL 
HOMOISOFLAVANONE INHIBITOR OF ENDOTHELIAL CELL GROWTH 
[This chapter forms portion of previously published following research paper and 
reproduced here with permission from PLoS ONE: 
Halesha Basavarajappa, Bit Lee, Xiang Fei, Daesung Lim, Breedge Callaghan, 
Julie A Mund, Jamie Case, Gangaraju Rajashekar, Seung-Yong Seo*, Timothy 
W Corson*. 2013. Synthesis and mechanistic studies of a novel 
homoisoflavanone inhibitor of endothelial cell growth. PLoS One 9(4): e95694. 
*Equal contributors.]  
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2.1 CHAPTER SUMMARY 
 
The main objective of this chapter is to demonstrate that a synthetic 
analogue of cremastranone shows biological activities which are similar to the 
natural product cremastranone. In this study, we present the synthesis of a novel 
homoisoflavanone isomer of cremastranone. Our compound, SH-11052, has 
antiproliferative activity against human umbilical vein endothelial cells, and also 
against more ocular disease-relevant human retinal microvascular endothelial 
cells (HRECs). Tube formation and cell cycle progression of HRECs were 
inhibited by SH-11052, but the compound did not induce apoptosis at effective 
concentrations. SH-11052 also decreased TNF-α induced p38 MAPK 
phosphorylation in these cells. Intriguingly, SH-11052 blocked TNF-α induced IκB-
α degradation, and therefore decreased NF-κB nuclear translocation. It decreased 
the expression of NF-κB target genes and the pro-angiogenic or pro-inflammatory 
markers VCAM-1, CCL2, IL8, and PTGS2. In addition SH-11052 inhibited VEGF 
induced activation of Akt but not VEGF receptor autophosphorylation. Based on 
these results we propose that SH-11052 inhibits inflammation induced 
angiogenesis by blocking both TNF-α and VEGF mediated pathways, two major 
pathways involved in pathological angiogenesis. Synthesis of this novel 
homoisoflavanone opens the door to structure-activity relationship studies of this 
class of compound and further evaluation of its mechanism and potential to 
complement existing antiangiogenic drugs. 
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2.2 INTRODUCTION 
During pathological conditions, levels of inflammatory cytokines such as 
TNF-α and IL-1 are elevated and these cytokines in turn promote angiogenesis 
along with VEGF (Oh et al., 1999; Yoshida et al., 1998). Hence targeting not only 
VEGF signaling but multiple proangiogenic signals is required to improve the 
efficacy of treatment for ocular diseases arising from pathological angiogenesis. 
At present there is currently no small molecule drug on the market to specifically 
prevent angiogenesis in the eye, hence there is a pressing need to develop 
specific novel small molecule drugs to treat these blinding eye diseases. 
In order to further explore the potential of homoisoflavanones as 
treatments for neovascular eye diseases, we synthesized a novel isomer of 
compound 1, 5,6-dihydroxy-3-(3-hydroxy-4-methoxybenzyl)-7-methoxychroman-
4-one, known as SH-11052 (compound 2, Fig. 1A). In this chapter I report this 
synthesis and show the anti-angiogenic properties of compound 2 in human 
retinal microvascular endothelial cells (HRECs). I also demonstrate that 
compound 2 blocks TNF-α induced NF-κB signaling and the VEGF-induced 
PI3K/Akt pathway, two major proangiogenic signaling pathways activated during 
inflammation induced angiogenesis. These results suggest that the compound 
exerts its anti-angiogenic properties by blocking inflammation-induced angiogenic 
pathways. 
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2.3. MATERIALS AND METHODS 
2.3.1 Materials Used 
Compound SH-11052 was synthesized by synthetic chemistry 
collaborators based in Gachon University, South Korea. The details of the 
synthesis are described elsewhere (Basavarajappa et al., 2014). HRECs and 
Attachment Factor were purchased from Cell Systems (Kirkland, WA, USA). 
Clonetics® HUVECs were purchased from Lonza (Walkersville, MD, USA). All 
cells were used between passages 5 and 7. Endothelial Growth Medium (EGM-
2) was prepared by mixing the contents of an EGM-2 “Bullet Kit” (Cat no. CC-
4176) with Endothelial Basal Medium (EBM) (Lonza). The EGM-2 “Bullet Kit” 
contains hydrocortisone, human fibroblast growth factor (hFGF), VEGF, R3-
insulin like growth factor (R3-IGF-1), ascorbic acid, human epidermal growth 
factor (hEGF), gentamycin and heparin along with 2% fetal bovine serum (FBS). 
Compound BAY 11-7082, caffeic acid phenethyl ester (CAPE), TNF-α, and α-
tubulin antibody were from Sigma (St. Louis, MO, USA), and human VEGF-165 
was from BioLegend (San Diego, CA, USA). The antibodies for p38 MAPK, NF-
κB p65 and VCAM-1 were obtained from Santa Cruz (Dallas, TX, USA) while the 
cleaved caspase-3, phospho p38 MAPK, Akt, phospho-Akt, VEGFR2, phospho-
VEGFR2, and IκB-α antibodies were from Cell Signaling (Danvers, MA, USA). 
Secondary antibodies were from Thermo Fisher Scientific (Pittsburgh, PA, USA). 
The TaqMan probes and 5ʹ-ethynyl-2ʹ-deoxyuridine (EdU) incorporation assay kit 
were procured from Life Technologies (Carlsbad, CA, USA). AbD Serotec 
(Kidlington, UK) was the source of the alamarBlue, while BD Biosciences (San 
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Jose, CA, USA) supplied the Matrigel. The Bradford reagent for protein 
estimation was prepared by dissolving 0.3 g of Coomassie G-250 (Pierce) in 500 
mL of 3 % perchloric acid. 
2.3.2. Cell Proliferation Assay 
In a 96-well clear bottom black plate, cells (2,500 cells per well) were 
seeded in a total volume of 100 µL EGM-2. After 24 hours of incubation of the 
plate at 37°C and 5% CO2, a DMSO solution of compound 2 was added in the 
concentration range of 0.5 nM to 500 µM (final DMSO concentration = 1%). The 
plate was then further incubated for 48 hours before adding 11.1 µL of 
alamarBlue reagent to each well. Four hours after the addition of alamarBlue, 
fluorescence readings with excitation and emission wavelengths of 560 nm and 
590 nm respectively were taken and the data were analyzed in GraphPad Prism 
software (v. 6.0). The dose response curve was generated and the GI50 value 
was calculated using the following equation: Y = 100/(1 + 10^(X – Log(GI50))). 
2.3.3. EdU Incorporation Assay 
Cells (25,000 per coverslip) were seeded onto coverslips coated with 
Attachment Factor placed in a 6-well plate and incubated with the indicated 
concentrations of compound 2 in EGM-2 for 24 hours at 37°C and 5% CO2. The 
cells were then serum starved for 8 hours and the medium was replaced with 
EGM-2 containing 10 µM EdU. The plate was further incubated for another 8 
hours before processing the cells for detection of labeled DNA (according to the 
manufacturer’s instructions for the Click-iT EdU assay kit). Images were taken 
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using an EVOS fluorescence microscope (AMG, Mill Creek, WA, USA) and the 
number of DAPI stained and EdU stained cells were counted in six randomly 
chosen fields using ImageJ software. 
2.3.4. In Vitro Angiogenesis Assay 
Matrigel assays were performed as previously described (Ponce, 2001), 
with slight modifications for the use of HRECs. Briefly, HRECs were starved 
overnight at 0.5% FBS in EBM-2 and plated on a 96-well plate at a density of 
7,500 cells/well over 50 µL of Matrigel high concentration basement membrane. 
Compound 2 was added at the indicated concentrations in EBM-2 + 1% FBS. 
Cells were observed every 2 hours by bright field microscopy at 40× 
magnification for tube formation. Closed units (polygons) were manually counted 
at 8 hours post plating and numbers normalized to the DMSO control. Assays 
were performed in triplicate. 
2.3.5. Caspase-3 Expression Assay 
Cells (25,000 per coverslip) were seeded onto coverslips coated with 
Attachment Factor and incubated at 37°C and 5% CO2 in EGM-2 until ~80 % 
confluence was achieved. The cells were then incubated for 4 hours with the 
indicated concentrations of compound 2. Staurosporine (SP; 1 µM) was used as 
a positive control. After the incubation, the cells were fixed in 4% 
paraformaldehyde for 20 min at room temperature followed by three quick 
washes in Tris buffered saline pH 7.4 (TBS). The cells were permeabilized by 
incubating with 0.5% Triton X-100 for 10 minutes and then blocked in 10% block 
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solution (DAKO, Glostrup, Denmark) in TBS plus 1% bovine serum albumin 
(BSA) for 1 hour. The cells were then incubated with cleaved caspase-3 (D175) 
antibody (1:200 dilution) overnight at 4°C. Dylight 555 conjugated goat anti-rabbit 
secondary antibody (1:400) was used to probe the cleaved caspase-3 antibody. 
The coverslips were mounted using Vectashield mounting medium containing 
DAPI (Vector Labs, Burlingame, CA, USA) for nuclear staining. The cells were 
imaged using an LSM 700 confocal microscope (Zeiss, Thornwood, NY, USA). 
2.3.6. NF-κB Nuclear Translocation Assay 
Cells (25,000 per coverslip) were seeded onto coverslips coated with 
Attachment Factor and incubated at 37°C and 5% CO2 for 24 hours in EGM-2. 
The cells were starved in 0.1% serum-EBM-2 for 8 hours followed by 0.1% 
serum-EBM-2 medium for one hour in the presence of different concentrations of 
compound 2. The cells were induced with 10 ng/ml TNF-α for 20 minutes and 
fixed with 4% paraformaldehyde solution for 20 min at room temperature. Cells 
were quickly washed three times in TBS and permeabilized by incubating with 
0.5% Triton X-100 for 10 minutes. The cells were blocked in 10% block solution 
(DAKO) in TBS plus 1% BSA followed by incubation with an antibody against NF-
κB p65 (1:50 dilution). Dylight 488-conjugated goat anti-mouse secondary 
antibody (1:200 dilution) was used to probe the NF-κB p65 antibody. The 
coverslips were mounted using Vectashield mounting medium containing DAPI 
(Vector Labs) for nuclear staining. The cells were imaged using an LSM 700 
confocal microscope (Zeiss). 
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2.3.7. VCAM-1 Expression assay 
Cells (25,000 per coverslip) were seeded onto coverslips coated with 
Attachment Factor and incubated at 37°C and 5% CO2 for 24 hours in EGM-2. 
The cells were starved in 0.1% serum-EBM-2 for 8 hours followed by incubation 
in 0.1% serum-EBM-2 medium for an hour in the presence of different 
concentrations of compound 2. The cells were challenged with 10 ng/ml of TNF-α 
for 24 hours and fixed with 4% paraformaldehyde solution for 20 minutes at room 
temperature. The coverslips were quickly washed three times in TBS and 
blocked using 10% block solution (DAKO) prepared in 1× TBS-1% BSA buffer. 
The coverslips were incubated with the antibody against VCAM-1 (1:100 dilution) 
for 16 hours at 4°C followed by three washes in TBS- 0.1% BSA buffer.  
Dylight555-conjugated secondary antibody (1:200) was used to probe for the 
VCAM-1 antibody. After three washes in TBS-0.1% BSA, the coverslips were 
mounted using Vectashield mounting medium containing DAPI nuclear stain. The 
cells were imaged using an LSM 700 confocal microscope. The images were 
analyzed for fluorescence signal intensity using MetaMorph software (Molecular 
Devices, Sunnyvale, CA, USA). 
2.3.8. qRT-PCR 
Cells (105 per well) were seeded in a 6-well plate and incubated for 24 
hours at 37°C and 5% CO2. The cells were then starved in 0.1% serum-EBM-2 
for 12 hours followed by incubation for an hour in the presence of different 
concentrations of compound 2. The cells were then challenged for 24 hours with 
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10 ng/ml TNF-α. Following incubation, cells were lysed and RNA was isolated 
using Trizol reagent (Life Technologies). cDNA was prepared from 80 ng total 
RNA using random primers and M-MuLV Reverse Transcriptase (New England 
Biolabs, Ipswich, MA, USA). RT-PCR reactions were set up using the TaqMan 
Fast Gene Expression Assay Kit according to the manufacturer’s instructions. 
FAM-labeled TaqMan probes for PTGS2 (Hs00153133_m1), CCL2 
(Hs00234140_m1), IL8 (Hs00174103_m1), and TBP (Hs99999910_m1) genes 
were used to monitor the expression levels of these genes. The qRT-PCR plate 
was read in a ViiATM 7 qPCR system (Life Technologies) and the data were 
analyzed using the ΔΔCt method. The expression levels of genes were 
normalized to TBP gene expression and calibrated to the DMSO-treated, 
unstimulated sample. 
2.3.9. Immunoblot 
HRECs were seeded at 105 cells/well in a 6-well plate and after 24 hours 
of incubation at 37°C, cells were serum starved in 0.1% serum-EBM-2 for 8 
hours. Cells were then treated with the indicated concentrations of compound 2 
for one hour before the addition of 20 ng/ml of TNF-α or 100 ng/ml VEGF. After 
20 minutes, cells were lysed in NP-40 Lysis buffer containing 25 mM HEPES pH 
7.4, 1% NP-40, 150 mM NaCl, 10% glycerol, 1 mM sodium orthovanadate, 10 
mM sodium fluoride, 1 mM sodium pyrophosphate, 1 mM PMSF, 2.5 mg/ml 
aprotinin, 1 mM pepstatin, and 1 mM leupeptin. Equal amounts of proteins (80 
µg), as measured by a Bradford assay, were run on 10% SDS-PAGE, transferred 
to PVDF membrane, blocked with 5% BSA in TBS-0.05% Tween-20 and 
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immunoblotted with the indicated primary antibodies (1:1000 in 1% BSA in TBS-
0.05% Tween-20) overnight at 4°C. After three washes in TBS-0.05% Tween-20, 
HRP-conjugated secondary antibodies (1:5000 in 5% BSA in TBS-0.05% Tween-
20) were applied for one hour at room temperature. After three washes, the 
protein bands were detected and densitized using ECL Prime western blot 
detection reagent (GE Life Sciences, Piscataway, NJ, USA) and an XRS gel 
documentation system running Quantity One software (Bio-Rad). Target protein 
band intensity was normalized to housekeeping gene α-tubulin. For 
phosphoprotein analysis, normalized signal of each phosphoprotein was 
expressed relative to the normalized total amount of that protein. 
2.3.10. Statistical Analysis 
EdU incorporation, tube formation, apoptosis, immunoblot, and VCAM-1 
staining assay data were analyzed by ANOVA with Dunnett’s post hoc tests for 
comparisons between drug treatments and control. All analyses were performed 
with GraphPad Prism (v. 6.0). A p-value <0.05 was considered statistically 
significant in all tests.	
2.4. RESULTS 
2.4.1. SH-11052 Inhibits Proliferation of HRECs 
It has been reported that compound 1 isolated from C. appendiculata 
showed antiproliferative effects with a 50% growth inhibitory (GI50) concentration 
value in the low micromolar range in a HUVEC proliferation assay (Kim et al., 
2008; Shim et al., 2004). In order to test if SH-11052 (2) has similar effects, the 
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proliferation of HUVECs induced by complete medium was monitored in the 
presence of compound 2 in the concentration range of 0.5 nM to 500 µM. As 
shown in Figure 2.1B, compound 2 inhibited HUVEC proliferation in a dose 
dependent manner with GI50 = 18 µM. Once the antiproliferative activity of 
compound 2 against HUVECs was confirmed, the proliferation of the more 
disease-relevant HRECs was tested in the presence of compound 2 in the same 
concentration range. As shown in Figure 2.1C, HREC proliferation was 
significantly inhibited by compound 2 with GI50 = 43 µM. In order to confirm the 
inhibition of cell proliferation, we monitored incorporation of 5-ethynyl-2’-
deoxyuridine (EdU) into endothelial cells in the presence of compound 2 (Figure 
2.2). DNA synthesis in both HRECs and HUVECs was significantly inhibited in a 
dose dependent manner by this compound.  
2.4.2. SH-11052 Inhibits In Vitro Angiogenesis without Inducing Apoptosis 
The effect of compound 2 on the angiogenic ability of HRECs was 
evaluated using an in vitro Matrigel tube formation assay. HRECs treated with 
compound 2 showed a significant reduction in their tube formation ability as 
compared to DMSO treated samples (Figure 2.3A). In the presence of compound 
2 at the GI50 value, there was a significant reduction in tube formation and the 
network of tubes was disrupted (polygon spaces in Figure 2.3A) and at 120 µM 
the tube formation ability was completely abolished (Figure 2.3B). However, even 
at 100 µM, compound 2 caused negligible apoptosis of HRECs as determined by 
cleaved caspase-3 staining (Figure 2.3C and 2.3D). 
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Figure 2.1. Homoisoflavanone SH-11052 inhibits proliferation of endothelial 
cells. The effects of SH-11052 (2), an isomer of the natural-source 
cremastranone 1 (A) on the proliferation of HUVECs (B) and HRECs (C) were 
tested by alamarBlue fluorescence in the concentration range of 0.5 nM to 500 
µM and shown as mean ± SEM relative to DMSO control. Dose response curves 
and indicated GI50 values were generated using GraphPad Prism software.  
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Figure 2.2. SH-11052 blocks DNA synthesis in endothelial cells. After 
treatment with the indicated concentrations of SH-11052 (2) and an EdU pulse, 
the HUVECs (A, B) and HRECs (C, D) were stained with DAPI (for nucleus - 
blue) and incorporated EdU (in proliferating cells – red) using a Click-iT kit (Life 
Technologies). The cells were counted from 6 different fields of a coverslip and 
the percentage of proliferating HUVECs (B) and HRECs (D) was calculated from 
the ratio of EdU stained cells to DAPI stained cells in each section (dots in the 
graphs) using ImageJ analysis software. Scale bars = 1 mm. 
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2.4.3. SH-11052 Inhibits the TNF-α Mediated NF-κB Pathway 
After establishing the anti-angiogenic activity of compound 2, we 
examined the mechanistic details of its activity in HRECs. As inflammation plays 
a crucial role in pathological angiogenesis (Klein et al., 2002; Rajashekhar et al., 
2011; Rajashekhar et al., 2006; Vanderslice et al., 1998), we examined the effect 
of compound 2 on inflammatory signaling in endothelial cells. HRECs were 
treated with different concentrations of compound 2 and then induced with TNF-
α, a known pro-inflammatory cytokine and inducer of NF-κB. Since NF-κB exerts 
its transcriptional activity in the nucleus, blockade of stimulus-induced nuclear 
translocation of NF-κB is an indication of NF-κB pathway inhibition (Tomita et al., 
1999). The nuclear translocation of NF-κB upon TNF-α stimulation was inhibited 
by compound 2 in a dose dependent manner as monitored by 
immunofluorescence (Figure 2.4A). IκB-α is an inhibitory protein that binds to NF-
κB and prevents its nuclear translocation. Upon TNF-α stimulation, IκB-α is 
phosphorylated and degraded, freeing NF-κB for nuclear translocation (Chen and 
Goeddel, 2002). In the presence of compound 2, the TNF-α-mediated 
degradation of IκB-α was significantly decreased in a dose dependent manner, 
further indicating that compound 2 is inhibiting NF-κB signaling (Figure 2.4 B-C). 
In order to confirm inhibition of the TNF-α pathway, we monitored the activating 
phosphorylation of p38 mitogen activated  
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Figure 2.3. SH-11052 inhibits in vitro angiogenesis without causing 
apoptosis. (A) Tube formation on Matrigel by HRECs in the presence of the 
indicated concentrations of 2. (B) Polygons formed (open spaces) were counted. 
Mean ± SEM of n=3 wells. *, p<0.05; ***, p<0.001 compared to DMSO control 
(ANOVA with Dunnett’s post hoc test). (C) HRECs were treated with indicated 
concentrations of 2 or staurosporine (SP) and stained with DAPI (for nucleus - 
blue) and activated caspase-3 antibody (red). (D). Percentage of HRECs 
undergoing apoptosis was calculated by counting number of caspase (red) 
stained cells compared to total (blue) cells using ImageJ software. Scale bars = 1 
mm. 
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protein kinase (MAPK), an important downstream target of the TNF-α pathway 
involved in cytokine induced cell proliferation (Liu et al., 2000). Compound 2 
inhibited phosphorylation of p38 MAPK in a dose dependent manner (Figure 2.4 
D-E).  
2.4.4. SH-11052 Decreases Levels of NF-κB Targets 
We confirmed NF-κB pathway inhibition by monitoring the expression of 
NF-κB induced genes in the presence of compound 2 (Figure 2.5). VCAM-1 is a 
cell adhesion molecule specifically expressed on endothelial cells and its 
expression is induced by NF-κB upon TNF-α signaling (Rajashekhar et al., 2007; 
Zhang et al., 2002). We monitored the expression of VCAM-1 in HRECs using 
immunofluorescence with increasing concentrations of compound 2. There was a 
significant dose-dependent decrease in VCAM-1 protein expression in the 
presence of compound 2 (Figure 2.5A & 2.5B). Similarly the mRNA expression of 
the pro-inflammatory molecules IL8, PTGS2 (COX2) and CCL2 (MCP-1), 
inducible by NF-κB, were decreased in the presence of compound 2, as 
monitored by qRT-PCR (Figure 2.5C).  
2.4.5. SH-11052 Inhibits VEGF-mediated Activation of PI3K/Akt Signaling 
As VEGF signaling is a major contributor to angiogenesis, we tested if 
compound 2 can inhibit VEGF signaling along with inflammation induced TNF-α 
signaling. Upon VEGF stimulation, VEGF receptor 2 (VEGFR2) 
autophosphorylates, leading to activation of the PI3K/Akt pathway(Hoeben et al., 
2004). Compound 2 did not inhibit phosphorylation of VEGFR2 but inhibited 
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activation of the downstream Akt in HRECs (Figure 2.6). Since TNF-α signaling 
also feeds through Akt to IKKα (Ozes et al., 1999), these results suggest that 
compound 2 might act at the level of PI3K or Akt to block both VEGF and TNF-α 
signaling. 
2.5. DISCUSSION 
In pathological ocular neovascularization such as that observed in ROP, 
DR and AMD, there is an increase in the levels of VEGF (Chen and Smith, 2007; 
Yoshida et al., 1997). Along with VEGF, inflammation plays a crucial role in 
pathological angiogenesis (Economopoulou et al., 2005; Rajashekhar et al., 
2011; Yoshida et al., 1998; Yoshida et al., 1997). This suggests that pathologic 
vessel growth as observed in ocular diseases is not only under control of VEGF 
(Carmeliet, 2003), but also intimately linked with inflammation leading to 
endothelial activation (Rajashekhar et al., 2007; Rajashekhar et al., 2006). Of the 
several cell signal transduction pathways studied, NF-κB pathways play an 
important role in inducing the expression of pro-angiogenic genes such as VEGF, 
VEGFR, IL8, VCAM1, CCL2, and PTGS2 after activation through TNF-α 
signaling (Klein et al., 2002; Royds et al., 1998; Yoshida et al., 1997). Based on 
the clinical evidence that anti-VEGF antibody therapy led to arterial 
thromboembolic complications and suggested a role for endothelial damage and 
inflammation (Ratner, 2004), a combination of anti-VEGF and anti-inflammatory 
therapy might be more beneficial in treating neovascular eye disease as 
compared to monotherapy. In favor of this hypothesis, in ROP experimental 
models, a combination of inhibitors of different pathways was found to be 
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Figure	2.4. SH-11052 inhibits TNF-α mediated NF-κB signaling. (A) After 
treating HRECs with the indicated concentrations of 2, p65 (green) was detected 
by immunofluorescence and nuclei (blue) stained with DAPI. Representative data 
from three independent experiments. Scale bars = 1mm. (B) The protein levels of 
IκB-α were measured after TNF-α treatment in the presence of the indicated 
concentrations of compound 2 by immunoblot. (D) The phosphorylation level of 
p38 MAPK in HRECs stimulated with TNF-α was monitored in the presence of 
the indicated concentrations SH-11052 by immunoblot. (C & E) Densitometry 
was performed using Quantity One software and analyzed using GraphPad 
Prism. 
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Figure 2.5. SH-11052 decreases the expression of NF-κB target genes. (A) 
Endothelial activation marker VCAM-1 (red) was detected by 
immunofluorescence in HRECs exposed to TNF-α ± 2. Scale bars = 1mm. (B) 
MetaMorph fluorescence intensity analysis of VCAM-1 staining in the presence of 
TNF-α and the indicated concentrations of 2, mean±SEM of n=5 fields; *, p<0.05  
**, p<0.01 compared to DMSO control (ANOVA with Dunnett’s post hoc test); 
representative data from two independent experiments. (C) qRT-PCR using 
TaqMan probes showed that mRNA levels of NF-κB target genes IL8 (interleukin-
8) (left panel), CCL2 (MCP-1) and PTGS2 (COX2) (right panel), all induced by 
TNF-α, were decreased in the presence of 2 in a dose dependent manner. 
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Figure 2.6. SH-11052 inhibits VEGF mediated Akt signaling. Phosphorylation 
of VEGFR2 (A) and Akt (C) was monitored in HRECs upon VEGF stimulation in 
the presence of varying concentrations of 2. (B & D) Densitometry was 
performed using Quantity One software and analyzed using GraphPad Prism. 
The lines indicate the mean ± SEM of three biological replicates, * indicates 
p<0.05 and ** indicates p<0.01 compared to VEGF treatment alone (ANOVA with 
Dunnett’s post hoc test).	
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highly significant in blocking new vessel formation (Friedlander, 2009). At 
present, the current antiangiogenic biologics only target VEGF signaling at the 
level of the receptor, therefore, the development of drugs targeting inflammatory 
signals provides an opportunity for new, combination anti-angiogenic therapies. 
Developing small molecules to include in such cocktails is therefore of significant 
interest and development of drugs which can inhibit multiple angiogenic 
pathways would greatly increase the efficacy of therapies. Towards this goal we 
have pursued SH-11052 as a small molecule inhibitor of retinal 
neovascularization, building on previous reports of the efficacy of a related 
homoisoflavanone (1) in animal models of ROP and choroidal neovascularization 
(Kim et al., 2007; Kim et al., 2008).  
In the present study our collaborator used a novel method based on a 
chalcone intermediate and a regioselective demethylation to synthesize the novel 
homoisoflavanone 2. This methodology adds to the diversity of 
homoisoflavanones that are synthetically tractable and will readily allow synthesis 
of novel analogs in future. I confirmed that our synthetic SH-11052 has similar 
effects on HUVECs to the natural-source compound 1 (Figure 1B). GI50 of the 
natural product 1 was reported as 0.5 µg/mL, or approximately 1.5 µM (Shim et 
al., 2004). 
Endothelial cells from different tissues have different gene expression 
patterns suggesting different physiological effects (Hesse and Moser, 2003). 
HUVECs are macrovascular endothelial cells which do not have specific 
relevance to the microvascular endothelial cells that are present in retinal 
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capillaries of the eye. Therefore, we tested SH-11052 in HRECs, where it proved 
similarly potent as an anti-proliferative molecule (Figure 2.1C), albeit at higher 
GI50, consistent with the hypothesis that microvascular endothelial cells differ 
from macrovascular endothelial cells. SH-11052 blocks proliferative progression 
through DNA synthesis in both HUVECs and HRECs (Figure 2.2). This is 
consistent with the documented G2/M phase cell cycle arrest induced by 1 in 
HUVECs (Kim et al., 2007). We have also demonstrated the in vitro anti-
angiogenic activity of 2 in a Matrigel HREC tube formation assay, similar to the 
effects of 1 in HUVECs (Kim et al., 2007). 
The novel anti-angiogenic mechanism of homoisoflavanones remains 
largely unexplored. In HUVECs, compound 1 induced expression of p21WAF1 
(CDKN1A), an inhibitor of the cyclin-dependent kinase Cdc2 (CDK1), which in 
turn is downregulated by compound 1 (Kim et al., 2007). Homoisoflavanone 1 
also blocked prostaglandin synthesis from arachidonic acid in a microsome 
assay, without marked effects on function of cyclooxygenases 1 and 2 as purified 
enzymes (du Toit et al., 2005). In keratinocytes, compound 1 inhibited the 
nuclear translocation of NF-κB under ultraviolet light-induced inflammatory 
conditions, suggesting a role of the compound in modulating inflammatory 
signals in these cells (Hur et al., 2010b). In this context, compound 1 also 
decreased phosphorylation of the MAPKs Jun N-terminal kinase (JNK), p38 
MAPK, and ERK. 
We examined if the activity of SH-11052 in HRECs may likewise be 
mediated through modulation of inflammatory signals. As NF-κB is the principal 
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mediator of inflammation induced signals (Tak and Firestein, 2001), we 
monitored NF-κB activation upon TNF-α stimulation in the absence or presence 
of compound 2 in HRECs. NF-κB is a transcription factor sequestered in the 
cytoplasm by association with IκB-α protein. Upon TNF-α stimulation, IκB-α is 
phosphorylated and degraded by the proteasome, releasing free NF-κB. The free 
NF-κB is then translocated into the nucleus and aids in the transcription of its 
target genes. Hence monitoring the protein levels of IκB-α and nuclear 
translocation of NF-κB upon TNF-α treatment are measures of the activation of 
the NF-κB pathway by inflammatory signals (Tak and Firestein, 2001). Indeed, 
we show that IκB-α degradation and nuclear translocation of NF-κB in HRECs 
are inhibited by compound 2 (Figure 2.4). Furthermore, compound 2 also 
inhibited the expression of NF-κB inducible pro-angiogenic and pro-inflammatory 
genes (Figure 2.5), suggesting a role for compound 2 in the inhibition of 
inflammation-induced pro-angiogenic signaling in HRECs.  
SH-11052’s suppressive effects on expression of IL8 and PTGS2 in 
HRECs are consistent with the observed effects of the natural product 1 in 
keratinocytes. To our knowledge, we show for the first time an effect of a 
homoisoflavanone on the endothelial activation marker and NF-κB target, VCAM-
1, and on the inflammatory marker CCL2. Thus, the data presented here are 
consistent with a function for compound 2 as an inhibitor of NF-κB signaling in 
HRECs. NF-κB has previously been implicated in pathological ocular 
angiogenesis (Omar et al., 2013; Yoshida et al., 1999). 
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This assertion of an NF-κB-dependent role for compound 2 can integrate 
others’ findings regarding the activities of the related compound 1 in other cell 
types as well. bFGF can act by signaling through phospholipase Cγ1 (Meyer et 
al., 2003; Raffioni et al., 1999), which activates protein kinase C (PKC) α via 
diacylglycerol. In turn, PKCα binds and activates IKKα, which phosphorylates 
and inactivates I-κB (Lallena et al., 1999). Thus, blockade of this pathway would 
inhibit cellular responses to bFGF, as seen with compound 1 in HUVECs (2004). 
NF-κB is a major transcription factor for inflammatory cytokines, and also for 
transcription of PTGS2 (Kang et al., 2007), consistent with the negative 
transcriptional effects of compound 1 on these genes and consequent inhibition 
of prostaglandin production in keratinocytes. Mitochondrial superoxide dismutase 
(SOD2) transcription is also activated by NF-κB (Maehara et al., 2000), 
potentially explaining increased reactive oxygen species generation after NF-κB 
inhibition mediated by compound 1 (Hur et al., 2010b). Moreover, blockade of the 
NF-κB pathway can deactivate MAPKs, as seen with compound 1 (Hur et al., 
2010b) in keratinocytes and compound 2 in HRECs (Figure 2.4). This may occur 
via sequestration of the MAPK kinase kinase TPL2 (tumor progression locus 2) 
by (inactive) p105NFKB1 (Yang et al., 2012). Finally, NF-κB inhibition can lead to 
upregulated p53-mediated transcription (Webster and Perkins, 1999), which 
could increase levels of p21WAF1 and decrease Cdc2 expression in response to 
treatment with compound 1 as previously seen in HUVECs (Kim et al., 2007). A 
role for both compounds 1 and 2 in the NF-κB pathway is also consistent with 
possible mechanisms for related isoflavones (Gupta et al., 2010), and NF-κB 
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pathway inhibition can block pathogenic ocular neovascularization (Yoshida et 
al., 1999). 
Compound 2 may be acting at the level of PI3K or Akt, since compound 2 
can inhibit VEGF-induced Akt phosphorylation, but not VEGFR2 phosphorylation 
(Fig. 2.6), and since PI3K/Akt serves as a point of integration of both VEGF and 
TNF signaling (Ozes et al., 1999). As a post-receptor VEGFR signaling inhibitor 
and TNF-α pathway inhibitor, compound 2 may serve as a lead molecule for 
targeting multiple proangiogenic pathways to improve the efficacy of treatment. 
Development of such molecules which target both VEGF and other inflammation 
induced proangiogenic signaling pathways might help in replacing or reducing 
the dose of anti-VEGF biologics. Future studies identifying the direct molecular 
interacting partners of homoisoflavanones in HRECs will be crucial for elucidating 
their precise anti-angiogenic mechanism as described in chapter 5, as well as 
optimizing the structures of these molecules prior to future therapeutic use 
(discussed in chapter 4), via a target-based drug discovery approach. 
In summary, we have synthesized a novel homoisoflavanone 2 and 
demonstrated its anti-angiogenic activity in retinal endothelial cells, and provided 
partial characterization of its molecular mechanism. Given SH-11052’s anti-
angiogenic properties, it will be important to fully elucidate the molecular 
mechanism of action of this compound. Our synthetic method also enables 
structure-activity profiling to obtain more potent anti-angiogenic molecules that 
can be tested in animal models of ocular neovascularization, both alone and in 
combination therapies. 
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Based on the success of synthesizing this compound, SH-11052, our 
synthetic chemistry collaborators attempted to synthesize cremastranone. In the 
next chapter I report the biological characterization of synthetic cremastranone. 
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CHAPTER 3. FIRST SYNTHESIS OF THE ANTI-ANGIOGENIC 
HOMOISOFLAVANONE, CREMASTRANONE 
 [This chapter forms portion of previously published research paper and 
reproduced here with permission from the Royal Society of Chemistry: Bit Lee, 
Halesha D. Basavarajappa, Rania S. Sulaiman, Timothy W. Corson* and Seung-
Yong Seo*. 2014. First synthesis of the antiangiogenic homoisoflavanone, 
cremastranone. Organic and Biomolecular Chemistry, 12, 7673. * Equal 
contributors]. My role in this project was to evaluate the biological properties of 
cremastranone. 
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3.1  CHAPTER SUMMARY 
An antiangiogenic homoisoflavanone, cremastranone, was synthesized for 
the first time. This scalable synthesis, which includes selective demethylation, 
could be used to develop lead molecules to treat angiogenesis-induced eye 
diseases. Synthetic cremastranone inhibited the proliferation, migration and tube 
formation ability of human retinal microvascular endothelial cells, important steps 
in pathological angiogenesis. The objective of this chapter is to characterize the 
biological activities of synthetic cremastranone in order to use it in mechanistic 
studies. 
3.2 INTRODUCTION 
So far, the syntheses of 5,7-dihydroxy-6-methoxyflavones and 5,7-
dihydroxy-6-methoxyhomoisoflavanone have been reported (Fig. 3.1) (Farkas et 
al., 1971; Farkas and Strelisky, 1970). In spite of its interesting biological 
activities and the synthesis of congeners, to the best of our knowledge, the 
synthesis of the anti-angiogenic natural product 1 (Fig.3.1) was not reported yet. 
To allow future profiling and development of this homoisoflavanone and its 
analogs, we need to develop a scalable synthesis suitable for quickly securing 
multi-gram quantities. During our previous synthetic approach toward 
cremastranone (Chapter 2), the regioisomer (SH-11052) was generated due to 
the challenge of selective deprotection of methyl phenyl ethers (Basavarajappa 
et al., 2014). In this chapter, we describe a short and efficient synthesis of 
cremastranone (1) featuring a solution to the issue of selective deprotection of 
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the methyl phenyl ether. Moreover, we show for the first time that synthetic 
cremastranone has biological properties consistent with the natural-source 
compound. 
3.3 METHODS 
3.3.1. Cell proliferation assay 
Alamar blue-based cell proliferation protocol was performed as described 
in chapter 2 (Section 2.3.2). 
3.3.2. EdU incorporation assay 
The EdU incorporaton assay was performed as described in chapter 2 
(Section 2.3.3). 
3.3.3. In vitro scratch assay 
HRECs (105) were seeded in each well of a 6-well plate coated with 
attachment factor. The cells were incubated in EGM-2 medium until confluent 
(~24 hours). The cells were then starved for 12 hours in serum free EBM-2 
medium. After starvation, using a sterile fine 10 µL micropipette tip, a straight 
scratch was introduced in the well and rinsed twice using EBM-2 medium to 
remove unbound cells and debris. Then cells were incubated in EGM-2 medium 
in the presence of the indicated concentrations of 1 at 37°C and 5% CO2. After 8 
hours, images were taken using the EVOS microscope and the number of 
migrated cells into the scratched area was counted. 
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3.3.4. In vitro Angiogenesis assay 
The tube formation assay was performed as described in Chapter 2 
(Section 2.3.4). 
3.4 RESULTS 
Synthetic chemist collaborator Dr. Seung-Yong Seo’s group based in 
South Korea carried out the synthesis of cremastranone and other intermediates. 
Our plan for the preparation of cremastranone entailed chromanone formation 
and demethylation of a methyl aryl ether. This strategy would permit significant 
flexibility in the synthesis of 1 and thereby adapt a platform that leads to a variety 
of derivatives for further structure-activity relationship studies. In addition, we 
envisioned our synthesis would become very useful for the synthesis of similar 
interesting homoisoflavanones. The details of synthesis and methods are 
described in the published paper (Lee et al., 2014). Previously, cremastranone 
isolated from C. appendiculata was tested for its anti-proliferative activity against 
an endothelial cell model, human umbilical vein endothelial cells (HUVEC), and 
the 50% growth inhibitory concentration (GI50) value was reported to be 1.5 µM 
(Shim et al., 2004). Hence, we tested the anti-proliferative activity of synthetic 
cremastranone 1 (Fig. 3.1) on HUVECs in an alamar blue fluorescent cell 
proliferation assay and the GI50 was observed to be 377 nM. The slightly higher 
potency of synthetic 1 might be attributed to a difference in the proliferation 
assays used. 
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Figure 3.1.  The structure of cremastranone (1) and its congeners.   
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Further, we tested the anti-proliferative activity of 1 against a more ocular 
disease relevant endothelial cell model, human retinal microvascular endothelial 
cells (HRECs). We observed clear dose dependent inhibition of HREC 
proliferation by 1 in complete medium with GI50 of 217 nM (Fig. 3.2a). In addition 
we also tested the proliferation of HRECs induced by vascular endothelial growth 
factor, a potent inducer of angiogenesis, in presence of 1 and measured the GI50 
to be comparable (276 nM). In chapter 2, I reported a GI50 of 43 µM for 
regioisomer SH-11052 (2), which differed in the positions of hydroxyl and 
methoxy groups on the ‘A’ ring at C6 and C7 as compared to 1. The importance 
of positions of the groups on the ‘A’ ring suggests that a structure-activity 
relationship can be established. 
We then measured the endothelial cell specificity of 1 by measuring the 
proliferation of non-endothelial ocular cell lines, Y79 (retinoblastoma), 92-1 (uveal 
melanoma) and ARPE-19 (retinal pigmented epithelium). The anti-proliferative 
potency of 1 on these non-endothelial cell lines was significantly lower than that 
of endothelial cells with GI50 values of 9.8 µM, 47 µM and >250 µM on Y79, 92-1 
and ARPE-19 cells respectively, indicating that compound 1 is highly specific 
toward endothelial cells. 
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Figure 3.2. Synthetic cremastranone (1) blocks in vitro angiogenesis of 
human retinal microvascular endothelial cells (HRECs) in a dose-
dependent manner. (a) The effect of 1 on proliferation of HRECs was tested 
using an alamar blue fluorescence assay. (b, e) In an EdU incorporation 
assay, 1 blocked DNA synthesis as evidenced by a decrease in incorporation 
of EdU (pink) into the nuclei of HRECs (nuclei, blue). (c, f) Tube formation by 
HRECs on Matrigel was blocked by 1; the extent of tube formation was 
measured as tubule length. (d) Migration of HRECs in a scratch-wound assay 
was inhibited by 1. Scale bars = 1mm. The data points in all graphs indicate 
mean ± SEM; ** represents P < 0.01; *** P < 0.001 (ANOVA with Dunnett’s 
post hoc tests). Each of the panels is representative of three independent 
experiments. 
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We further confirmed the inhibition of HREC proliferation by 1 in a 
secondary assay by monitoring the incorporation of EdU into DNA of endothelial 
cells in the presence of different concentrations of 1. In this EdU incorporation 
assay, compound 1 inhibited the DNA synthesis of HRECs in a dose dependent 
manner (Fig 3.2c). 
After establishing the inhibition of HREC proliferation by 1, we tested its 
anti-angiogenic activity in vitro. Migration is an important step in the angiogenesis 
process, wherein endothelial cells move from pre-existing capillaries to the site of 
blood vessel formation. We measured this ability of HRECs to migrate using the 
standard scratch-wound assay, in which HRECs were allowed to grow to 
confluency, then a scratch was introduced and movement of endothelial cells into 
the scratched area from the surrounding population was measured in presence 
of various concentrations of 1 (Fig 3.2b). The migration of HRECs was inhibited 
by 1 in a dose dependent manner. We also tested the ability of HRECs to form 
tubes in vitro in a Matrigel tube formation assay, which recapitulates in vitro all 
events of physiological angiogenesis. Cremastranone 1 prevented the formation 
of closed tube structures in a dose dependent manner as measured by both tube 
length (Fig. 2d) and number of polygons formed. This is consistent with previous 
findings with the natural-source cremastranone in HUVECs (Shim et al., 2004). 
3.5 DISCUSSION 
In summary, a novel, scalable strategy to synthesize biologically active 
cremastranone was developed by our collaborator, and the resulting compound 
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was tested in cell models. Together, these results confirm the anti-angiogenic 
activity of synthetic cremastranone 1 in a disease-relevant cell type, and thereby 
pave the way for development of analogues with higher potency and better 
pharmacological properties to treat blinding ocular diseases caused by 
pathological angiogenesis.  
The scalable synthesis of synthetic cremastranone is very important to 
decipher the biological mechanism of action of cremastranone. Most of the 
biological methods used in understanding the mechanism of action require 
moderate to high quantities of cremastranone, which is difficult to obtain from 
plant sources as described in literature. The chemical synthesis of 
cremastranone removed this obstacle and also paved the way to synthesize 
more analogues to improve the potency and selectivity. Towards this end we 
pursued structure-activity relationship studies as described in chapter 4 in order 
to find potent and selective compounds which have high potency on HRECs and 
less activity on other endothelial and non-endothelial ocular cells. 
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CHAPTER 4. SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL 
HOMOISOFLAVONOIDS FOR RETINAL NEOVASCULARIZATION. 
[This chapter was previously published in the following research article and 
reproduced here with permission from the American Chemical Society: Halesha 
D. Basavarajappa, Bit Lee, Hyungjun Lee, Rania S. Sulaiman, Hongchan An, 
Carlos Magaña, Mehdi Shadmand, Alexandra Vayl, Gangaraju Rajashekhar, 
Eun-Yeong Kim, Young-Ger Suh, Kiho Lee, Seung-Yong Seo, Timothy W. 
Corson. 2015. Synthesis and biological evaluation of novel homoisoflavonoids for 
retinal neovascularization. Journal of Medicinal Chemistry. 58(12):5015-27]. 
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4.1 CHAPTER SUMMARY 
Eye diseases characterized by excessive angiogenesis such as wet age-
related macular degeneration, proliferative diabetic retinopathy, and retinopathy 
of prematurity are major causes of blindness. Cremastranone is an anti-
angiogenic, naturally occurring homoisoflavanone with efficacy in retinal and 
choroidal neovascularization models and antiproliferative selectivity for 
endothelial cells over other cell types. We undertook a cell-based structure-
activity relationship study to develop more potent cremastranone analogs, with 
improved antiproliferative selectivity for retinal endothelial cells. Phenylalanyl-
incorporated homoisoflavonoids showed improved activity and remarkable 
selectivity for retinal microvascular endothelial cells. A lead compound inhibited 
angiogenesis in vitro without inducing apoptosis, and had efficacy in the oxygen-
induced retinopathy model in vivo. 
4.2 INTRODUCTION 
In chapters 3 and 2 I showed that a natural product homoisoflavanone, 
cremastranone (1; Figure 1), and a regioisomer SH-11052 (2) inhibit 
angiogenesis in vitro, with some selectivity for blocking proliferation of endothelial 
cells over other ocular cell types. Selectivity for antiproliferative effects on 
microvascular endothelial cells (such as those in the eye) over macrovascular 
endothelial cells and non-endothelial cell lines is suggestive of a desirable lack of 
off-target cytotoxicity in vivo (Sulaiman et al., 2014). Indeed, cremastranone 
inhibits ocular angiogenesis, without obvious toxicity, in mouse models of laser-
induced choroidal neovascularization (Kim et al., 2008) and oxygen-induced 
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retinopathy (OIR) (Kim et al., 2007), animal models recapitulating some of the 
features of wet AMD and ROP respectively.  
Even though cremastranone’s antiangiogenic activity is well established, 
other homoisoflavonoids have not been extensively explored for their effects on 
endothelial cells. One compound, (E)-3-(3-hydroxy-4-methoxybenzylidene)-6-
methyl-4-chromanone was shown to have submicromolar antiangiogenic effects 
in vitro and efficacy in a laser-induced choroidal neovascularization model (Kim 
et al., 2008), while a related compound (E)-3-(2-methoxybenzylidene)-4-
chromanone was shown to have antiproliferative effects on human umbilical vein 
endothelial cells (HUVECs) (Ivanova et al., 2013). Of natural-source 
homoisoflavanones, methylophiopogonanone B blocked HUVEC angiogenesis 
and the hypoxic response in vitro (Hasebe et al., 2003), while very recently 
methylophiopogonanone A was shown to block brain endothelial cell activation 
(Lin et al., 2015). In addition, considerable work has documented antiangiogenic 
effects of the related chalcones, flavones and flavanones (Fotsis et al., 1997). 
However, to our knowledge no systematic exploration of this class of compounds 
as antiangiogenic agents has been reported. 
 Multiple signaling pathways are modulated by cremastranone (Kim et al., 
2007). It induces expression of p21WAF1 (CDKN1A), an inhibitor of the cyclin-
dependent kinase Cdc2 (CDK1). It also blocks prostaglandin synthesis from 
arachidonic acid (du Toit et al., 2005); and decreases phosphorylation of the 
mitogen activated protein kinases. Finally, it blocks nuclear translocation of NF-
κB and production of inflammatory cytokines ( Hur et al., 2010). The search for 
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direct molecular targets is underway. However, its exact mechanism of action 
remains unknown, rendering a cell-based analysis of efficacy the most 
appropriate route to developing novel derivatives. Here, we describe 
development of a structure-activity relationship of homoisoflavonoids for inhibiting 
proliferation of endothelial cells, which resulted in identification of potent, 
microvascular endothelial-cell specific antiangiogenic molecules for lead 
optimization. Using 1 as our primary scaffold, we envisioned homoisoflavonoid 
analog design by which several substituents on the A and B rings could be varied 
as shown in Fig. 4.1. We planned to synthesize homoisoflavonoids with highly 
oxygenated substitutions such as methoxy and hydroxy on the A ring (du Toit et 
al., 2010; Mulholland et al., 2013), whereas those with a wide range of 
substitution patterns on the B ring would be anticipated to exhibit more efficient 
and selective antiproliferative activity than natural product homoisoflavonoids. 
 
Figure 4.1. Homoisoflavonoid analog design. 
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4.3 METHODS 
4.3.1 Chemistry Methods 
Synthetic chemistry collaborator Dr. Seung-Yong Seo’s group carried out 
the syntheses of all the homoisoflavonoid analogues. The details of the chemistry 
methods and results have been published (Basavarajappa et al., 2015).  
4.3.2  Materials 
The cells and culture media used are as described in chapter 2 (Section 
2.3.1). 
4.3.3 Cell proliferation assay 
The detailed protocol for monitoring the cell proliferation is described in 
chapter 2 (Section 2.3.2). 
4.3.4 EdU incorporation assay 
A complete Protocol for monitoring the EdU incorporation in HRECs has 
been described in chapter 2 (Section 2.3.3). 
4.3.5 Caspase-3 immunofluorescence assay 
The assay was carried out as described in chapter 2 (Section 2.3.5).  
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4.3.6 TUNEL assay  
Cells (25,000 per coverslip) were seeded on each coverslip coated with 
attachment factor in a 6-well plate and grown overnight in EGM-2 medium. Next 
day, fresh medium with the indicated concentrations of compound was added to 
cells and they were incubated for 4 hours. Cells were then fixed in 4% 
paraformaldehyde prepared in PBS for 20 minutes at room temperature. The 
coverslips were washed twice in PBS and incubated further for 20 min in 0.25% 
Triton X-100 in PBS.  Then coverslips were washed in PBS twice and apoptotic 
cells were visualized using the Click-iT TUNEL assay kit as per the 
manufacturer’s instructions, with DAPI counter-stain. The percentage of apoptotic 
cells was counted on three low-power fields per coverslip using Image J software 
and analysed using GraphPad Prism software (v. 6.0). 
4.3.7 In vitro scratch-wound assay 
The assay was carried out as described in chapter 3 (Section 3.3.3).  
4.3.8  In vitro Angiogenesis assay 
A Matrigel based tube formation assay was performed to monitor the tube-
formation ability of HRECs in the presence of compound as described in chapter 
2 ( Section 2.3.4).  
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4.3.9 Oxygen induced retinopathy (OIR) mouse model 
All animal experiments were approved by the Indiana University School of 
Medicine Institutional Animal Care and Use Committee and adhered to all 
standards set forth in the Association for Research in Vision and Ophthalmology 
Statement for the Use of Animals in Ophthalmic and Vision Research. OIR in 
mice was induced as described (Smith et al., 1994). Briefly, newborn C57BL/6 
mice pups along with nursing mother were incubated in a hyperoxia chamber 
(75% O2) from postnatal day (P)7 to P12. On day P12, pups were anesthetized 
using isoflurane and 0.5 µL of vehicle/anti-VEGF/compound was intravitreously 
injected into each eye under a dissecting microscope. The final estimated 
concentration of anti-VEGF antibody and compound in the vitreous of each eye 
was 5 ng and 1 µM respectively. The experimenters were masked to the identity 
of the treatments throughout experimentation and data analysis. After the 
injections, pups along with the nursing mother were returned to normoxia (room 
air) conditions from P12 to P17. On day P17, pups were killed and the eyes were 
enucleated and fixed in 4% paraformaldehyde for 4 hours. Then retinas were 
isolated under a dissecting microscope. Retinas were washed twice in PBS and 
then permeabilized for 2 hours in 0.1% Triton X-100 in 10% goat serum prepared 
in PBS. Then 1:200 diluted isolectin B4-Alexa 488 in 10% goat serum was added 
to each retina and incubated overnight at room temperature protected from light. 
After the incubation, retinas were washed 4 times in PBS with each wash lasting 
for 15 minutes. Retinas were incised into four sections on a glass slide and 
mounted using Vectashield mounting medium. Using the LSM700 confocal 
		 72 
microscope, approximately 20 images were taken for each retina with a 10X 
objective and all of these images were stitched using Adobe Photoshop CS5. 
Retinal neovascularization was quantified as described (Smith et al., 1994) using 
Adobe Photoshop CS5 software. 
4.3.10 Statistical analysis 
The data obtained from all experiments were analyzed by one-way 
ANOVA with Dunnett’s post hoc tests for comparisons between drug treatments 
and control. All analyses were performed using GraphPad Prism software (v.6.0). 
A p value of <0.05 was considered statistically significant in all tests. 
 
4.4 RESULTS AND DISCUSSION 
4.4.1. Biological Evaluation of A-ring Modified Homoisoflavanones  
Our chemist collaborator synthesized a homoisoflavanone series modified 
on the A ring. Of these, the majority of synthetic compounds except 
cremastranone exhibited weak inhibitory activity of cell proliferation and poor 
selectivity for human microvascular retinal endothelial cells (HRECs) compared 
to macrovascular human umbilical vein endothelial cells (HUVECs) and human 
ocular tumor cell lines 92-1 (uveal melanoma) and Y79 (retinoblastoma) (Table 
4.1). Cremastranone showed potent inhibitory activity of HREC and HUVEC 
proliferation, as discussed in chapter 3, whereas regioisomers with the different 
site-combinations of hydroxy and methoxy groups on the A ring had lower activity 
than the natural compound. Compounds 8 and 9 lost the inhibitory activity on 
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HREC cell proliferation, while homoisoflavanones 10 and 11 functionalized only 
with methoxy groups had good activity. Although compound 10 with trimethoxy 
on C5, C6 and C7 did not show stronger activity than cremastranone, it did show 
good selectivity for HRECs over other cell types including HUVECs. Thus, it was 
chosen as the starting point for further analogs in order to discover potent, 
microvascular endothelial-cell specific, antiangiogenic agents and to expand 
chemical space.  
4.4.2. Biological Evaluation of B-ring Modified Homoisoflavanones  
A series of homoisoflavanones modified on the B ring were evaluated 
(Table 4.2). Compared to the 3-benzyl-4-chromanones 10 and 11, 3-
benzylidene-4-chromanones 7b and 7c did not exhibit satisfactory activity 
against HRECs nor selectivity. On the other hand, 3-(3′,4′-disubstituted-
benzylidene)-4-chromanones (7d~7h) with a methoxy group at the C4′ position 
had moderate anti-proliferative activity (GI50 = 3~6 µM for HRECs), although still 
lacked selectivity. 3-Benzylidene-4-chromanones substituted on either C2′ or C4′ 
had substantially decreased inhibitory activity on HREC proliferation. Additionally, 
the bulkier benzyl group at the C4 position led to lower activity than the hydroxyl 
or methoxy group (7i vs 7j, 7k vs 7l). 
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Table 4.1 Growth inhibitory activity (GI50, µM) of A-ring modified 
homoisoflavanones on the proliferation of microvascular (HREC), macrovascular 
(HUVEC) and ocular tumor (92-1 and Y79) Cells. 95% confidence interval shown 
in parentheses. 
 
Cpd A ring HREC HUVEC 92-1 Y79 
1 
 
0.22 
(0.12 – 0.39) 
0.38 
(0.24 – 0.59) 
48 
(17 – 132) 
9.8 
(2.1 – 45) 
2 
 
45 
(26 – 75) 
18 
(16 – 21) 
10 
(4.4 – 23) 
>100 
8 
 
>100 >100 >100 >100 
9 
 
>100 44 
(34 – 58) 
>100 >100 
10 
 
2 
(0.81 – 5.1) 
12 
(2.7 – 55) 
>100 >100 
11 
 
1.6 
(1.0 – 2.6) 
2.5 
(0.87 – 7.1) 
>100 4.2 
(2.0 – 9.1) 
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Table 4.2 Growth inhibitory activity (GI50, µM) of B-ring modified 3-benzylidene-4-
chromanone analogs. 95% confidence interval shown in parentheses. 
 
Cpd B ring HREC HUVEC 92-1 Y79 
7b 
 
46 
(17 – 122) 
5.6 
(3.2 – 9.8) 
0.22 
(0.061 – 
0.81) 
44 
(22 – 89) 
7ca 
 
42 
(12 – 146) 
15 
(4.4 – 51) 
>100 
 
14 
(7.2 – 25) 
7d 
 
4.3 
(1.9 – 9.7) 
16 
(5.2 – 49) 
3.5 
(1.4 – 9.0) 
33 
(6.1 – 
180) 
7e 
 
3.9 
(1.9 – 8.1) 
12 
(7.6 – 18) 
1.1 
(0.34 – 
3.6) 
2.8 
(1.5 – 5.1) 
7f 
 
4.8 
(2.2 – 11) 
15 
(7.2 – 31) 
12 
(6.5 – 24) 
2.2 
(0.72 – 
6.4) 
7g 
 
5.6 
(2.6 – 12) 
3.2 
(1.4 – 7.3) >100 
6.1 
(3.4 – 11) 
7h 
 
2.8 
(1.1 – 7.1) 
7.6 
(3.2 – 18) 
7.0 
(1.9 – 26) 
9.8 
(4.1 – 23) 
7i 
 
3.3 
(1.7 – 6.4) 
6.2 
(5.1 – 7.7) 
26 
(8.6 – 77) 
5.2 
(3.2 – 8.2) 
7j 
 
35 
(14 – 83) 
52 
(27 – 100) 
68 
(25 – 186) 
14 
(8.7 – 24) 
7k 
 
7.6 
(2.7 – 22) 
5.0 
(2.2 – 11) 
9.5 
(4.8 – 19) 
4.0 
(0.86 – 19 
7l 
 
72 
(18 – 277) 
43 
(9.1 – 204 >100 
32 
(12 – 88) 
 
a. 3-(3′-hydroxy-4′-methoxybenzylidene)-5,7-dimethoxychroman-4-one 
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In contrast to the 3-benzylidene-4-chromanones with a planar 
conformation, the freedom of rotation of 3-benzyl-4-chromanones might affect the 
selectivity for HRECs over human ocular tumor cell lines (Table 4.3). Mainly 3-
benzyl-4-chromanones bearing methoxy on C4′ of the B ring were evaluated 
along with 12a, which shows little antiproliferative activity. Aniline 12b showed 
excellent antiproliferative activity, but ester 12c and acid 12d showed little or no 
antiproliferative activity. Benzyl (12e) and carbamoyl (12i) compounds were 
found to be weak growth inhibitors. Interestingly, introduction of acyl groups such 
as benzoyl (12f), cinnamoyl (12g) and dihydrocinnamoyl (12h) strongly increased 
activity with GI50 values of 0.14~0.65 µM for HRECs. Moreover 12f~12h were 
selective for HREC inhibition over HUVECs, Y79, and 92-1 cells. The 
antiproliferative activities were obviously dependent on the substitution pattern of 
the B ring. 
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Table 4.3 Growth inhibitory activity (GI50, µM) of B-ring modified 3-benzyl-4-
chromanone analogs. 95% confidence interval shown in parentheses. 
 
Cpd B ring HREC HUVEC 92-1 Y79 
12a 
 
>100 >100 >100 >100 
12b 
 
1.1 
(0.29 – 
4.4) 
0.51 
(0.11 – 
25) 
>100 >100 
12c 
 
18 
(6.1 – 50) 
17 
(5.1 – 57) >100 
40 
(24 – 66) 
12d 
 
>100 92 (27 – 317) >100 >100 
12e 
 
22 
(13 – 40) >100 
61 
(14 – 278) 
20 
(8.1 – 51) 
12f 
 
0.65 
(0.26 – 
1.6) 
>100 >100  >100 
12g 
 
0.17 
(0.030 – 
0.97) 
>100 >100 >100 
12h 
 
0.22 
(0.064 – 
0.77) 
38 
(13 – 109) >100 >100 
12i 
 
49 
(17 – 141) >100 >100 
24 
(6.1 – 97) 
 
a. CIN: cinnamoyl, DCI: dihydrocinnamoyl, DEC: N,N-diethylcarbamoyl. 			
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4.4.3. Biological Evaluation of Homoisoflavanones Coupled with Amino 
Acids on the C3′ position 
Encouraged by the potent activity of aryl esters (12f~12h), phenol 10 and 
aniline 12b were coupled with some N-protected amino acids to obtain the ester 
(14a~14j) and amide (15a-15c) analogs, respectively. Interestingly, 14a (also 
called SH-11037) which was given by coupling 10 with Boc-Phe-OH showed the 
most potent activity with GI50 = 55 nM against HRECs (Table 4.4; Figure 4.2A). 
Moreover 14a selectively inhibited HREC proliferation about 14-fold over 
HUVECs, 218-fold over Y79, and >1000-fold over 92-1, suggestive of cytostatic 
effects on HRECs rather than general cytotoxicity. The analogs (14b and 14c) for 
which 10 was coupled with Boc-Tyr(Bn)-OH and Boc-Tyr(Allyl)-OH had similar 
activity to 14a, potentially indicating that a bulkier (or longer) chemical spacer to 
the phenyl ring of the phenylalaninyl moiety is not detrimental to potency. An 
isoleucinyl analog (14d) had lower antiproliferative activity, whereas analogs 
(14e, 14f and 14g) generated with Boc-Leu-OH, Boc-homophe-OH and Cbz-
Phe-OH have more preferable activity and selectivity to cremastranone. The 
antiproliferative activity of ethylurea (14i), butylurea (14j) and sulfonamide (14j) 
analogs was not improved. Noteworthy, the inhibition of HREC proliferation with 
N-arylamide analogs (15a~15c) decreased substantially, compared with the 
corresponding phenyl ester analogs (14a~14c). Conversely, N-arylaminde 
analogs were considered to be moderate inhibitors against 92-1 and Y79 cells 
rather than antiangiogenic compounds.  
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Table 4.4 Growth inhibitory activity (GI50, µM) of homoisoflavonoids comprising 
amino acids on the C3′ position of the B-ring. 95% confidence interval shown in 
parentheses. 
 
 
 
Cpd B ring HREC HUVEC 92-1 Y79 
14a 
(SH-
110
37)  
0.055 
(0.032 – 
0.094) 
0.75 
(0.37 – 1.5) 
>100 
12 
(5.7 – 25) 
14b 
 
0.51 
(0.26 – 
1.0) 
>100 
 >100 >100 
14c 
 
0.16 
(0.020 – 
1.3) 
0.091 
0.013) – 
0.63) 
>100 
52 
(17 – 166) 
14d 
 
3.1 
(1.3 – 
7.4) 
>100 >100 24 
(7.1 – 79) 
14e 
 
0.13 
(0.026 – 
0.69) 
>100 >100 >100 
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14f 
 
0.17 
(0.035 – 
0.82) 
>100 >100 >100 
14g 
 
0.14 
(0.027 – 
0.73) 
>100 >100 >100 
14h 
 
1.0 
(0.031 – 
3.6) 
34 
(7.2 –165 
 
98 
(37 – 265) 
48 
(33 – 69) 
 
14i 
 
1.4 
(0.73 – 
2.4) 
>100 >100 64 
(26 –158) 
14j 
 
1.5 
(0.41 – 
5.4) 
22 
(11 – 43) 
>100 
 >100 
15a 
 
22 
(16 – 32) 
8.6 
(1.2 – 6.1) 
3.1 
(0.93 – 10) 
4.7 
(1.2 – 18) 
15b 
 
>100 >100 >100 
0.39 
(0.12 – 1.3) 
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15c 
 
13 
(9.7 – 17) 
4.5 
(1.2 – 17) 
1.9 
(0.65 – 5.3) 
2.5 
(1.4 – 4.6) 
 
a. PB: p-benzyloxybenzyl, PA: p-allyloxybenzyl, PT: p-(tert-butoxy)benzyl. 
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4.4.4. Validation of a Potent Cremastranone Derivative In Vitro 
In alamarBlue proliferation assays, 14a (SH-11037) had the highest 
potency of any compound tested. In addition, it was more potent and endothelial-
cell specific than previously described antiangiogenic homoisoflavonoids 
(Falkenstein et al., 2008; Hasebe et al., 2003; Ivanova et al., 2013; Lee et al., 
2014a). Given this, I tested it in a secondary cell proliferation assay, which 
monitors the incorporation of a thymidine analogue 5-ethynyl-2′-deoxyuridine into 
DNA of proliferating HRECs. Here, I confirmed the dose-dependent inhibition of 
HREC proliferation by 14a (Fig. 4.2a). 
After establishing the antiproliferative activity of this promising lead, we 
further tested its antiangiogenic activities in vitro. First we monitored the 
migration of HRECs, testing this important property of endothelial cells during 
blood vessel formation in the presence of 14a in a scratch wound assay (Fig. 
4.2B). 14a blocked the ability of HRECs to migrate in a dose dependent manner. 
Then we tested the ability of HRECs to form tubes in the presence of 14a in a 
Matrigel tube formation assay, an in vitro assay that recapitulates most of the 
events of physiological angiogenesis such as migration, proliferation, and cell-cell 
adhesion. 14a inhibited the tube formation ability of HRECs in the Matrigel assay 
at sub micromolar concentrations (Fig. 4.2C). Although 14a did not induce 
changes in cell morphology in these assays, since the compound was so potent 
in inhibiting tube formation, we tested if 14a induces apoptosis in HRECs. We 
employed both activated caspase (Fig. 4.2D) and TUNEL assays (Fig. 4.5) to 
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monitor the apoptosis of HRECs in the presence of different concentrations of 
14a. We observed less than 10% HREC cells undergoing apoptosis treated with 
up to 2 µM 14a, indicating that the compound may not be cytotoxic at effective 
concentrations. Furthermore, a trypan blue exclusion assay (Fig. 4.6) confirmed 
that treated HRECs retained viability, further implicating a cytostatic rather than 
cytotoxic mechanism for this compound. This finding was further supported by 
analysis of the cell cycle profile (Fig. 4.4) in HRECs treated with 14a, which 
revealed a dose-dependent G2/M phase blockade with few sub-G0 cells as 
documented previously for cremastranone. These results established that 14a is 
a potent inhibitor of angiogenesis in vitro.  
		 84 
 
Figure 4.2. Compound 14a (SH-11037) inhibits angiogenic behavior of 
HRECs in vitro. (A) Dose-response of the effects of 14a on HREC proliferation 
as measured by alamarBlue fluorescence. (B) 14a dose-dependently inhibits 
migration of HRECs in a scratch-wound assay. (C) 14a dose-dependently inhibits 
tube formation of HRECs on Matrigel. (D) 14a caused negligible apoptosis as 
assayed by activated caspase 3 (pink) immunofluorescence. 1 µM staurosporine 
(SP) is positive control. DAPI (blue) indicates normal nuclear morphology. Error 
bars indicate SEM, n=3, representative results from at least triplicate 
experiments. *P<0.05, **P<0.01 and ***P<0.001. Scale bars = 200 µm. 
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Figure 4.3. Compound 14a (SH-11037) inhibits in vitro proliferation of 
HRECs as measured by EdU incorporation assay. The nuclei of all cells are 
labelled with DAPI (blue) and actively dividing cells are labelled with EdU (pink). 
Error bars indicate SEM, n = 3, representative results from at least triplicate 
experiments. **** P<0.0001. 
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Figure 4.4. Compound 14a (SH-11037) arrests HRECs at G2/M cell cycle 
stage as monitored in propidium iodide based flow cytometry assay. 
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Figure 4.5. Compound 14a does not induce apoptosis significantly, as 
evidenced by TUNEL assay. The nuclei of all cells are shown in blue (DAPI 
staining) and TUNEL+ cells undergoing apoptosis are shown in red. Error bars 
indicate SEM, n = 3, representative results from at least triplicate experiments. 
Scale bars = 200 µm. 
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Figure 4.6. Viability of HRECs is not significantly altered by compound 14a as 
monitored in Trypan blue exclusion assays. Error bars indicate SEM, n = 3, 
representative results from triplicate experiments.  
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4.4.5. In vivo efficacy of a Potent Cremastranone Derivative  
After establishing antiangiogenic activity of 14a in vitro, we next explored 
the in vivo efficacy of this compound in preventing neovascularization in the OIR 
mouse model. Intravitreal injection of 14a to a final concentration of 1 µM in each 
eye significantly inhibited retinal neovascularization in OIR mice as compared to 
vehicle. Moreover, efficacy of the compound in vivo was similar to that observed 
with standard-of-care anti-VEGF antibody treatment (Fig. 4.7). We did not 
observe any overt systemic or ocular toxicity in mice treated with 14a, or gross 
morphological changes in the retinal vasculature. However, more extensive 
toxicological assessment of 14a remains to be done. 
The in vivo antiangiogenic activity of 14a observed here provides evidence 
that novel synthetic homoisoflavonoids that show potent and selective 
antiangiogenic activity in vitro can be used as lead molecules to develop drugs 
for treatment of ocular diseases arising from pathological angiogenesis. 
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Figure 4.7. Homoisoflavonoid 14a (SH-11037) inhibits retinal 
neovascularization in the OIR mouse model. Retinal whole mounts from 
treated mice were stained for blood vessels using Alexa-488-conjugated isolectin 
and imaged by confocal microscopy; neovascular area was measured using 
Adobe Photoshop. Error bars indicate SEM, n=6. **P<0.01 vs. vehicle, ANOVA 
with Dunnett’s post hoc tests. Dr. Rajashekar Gangaraju performed intravitreal 
injections and Alexandra Vayl maintained the animals in the oxygen chamber. 
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4.5. CONCLUSION 
We synthesized a series of homoisoflavonoids from chroman-4-ones, 
including successfully synthesizing the natural product cremastranone. 
Antiproliferative compounds with endothelial cell specificity, with a 
homoisoflavonoid-based scaffold, were developed as potent inhibitors of 
angiogenesis. The scaffold is sensitive to changes on the substituents on both 
the A and B rings. Exploring modification at the C3′ position revealed that 
addition of N-carbamate amino acids improved inhibitory activity on HREC 
proliferation. The most potent phenylalanyl-incorporated 14a showed improved 
activity and remarkable selectivity for retinal microvascular endothelial cells, with 
antiangiogenic efficacy in vitro and in the oxygen-induced retinopathy model in 
vivo. 
Now it is very well established that synthetic cremastranone shows similar 
biological activity to that of its natural counterpart and it can be synthesized in 
scalable quantities for use in mechanistic studies. Also, during SAR studies 
potential sites for conjugating the cremastranone analogues to linker-biotin 
complex have been identified. Using this knowledge, affinity reagents could be 
synthesized and used in pull-down experiments to identify the cremastranone 
binding proteins as described in the next chapter. 
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CHAPTER 5. FERROCHELATASE IS A THERAPEUTIC TARGET FOR 
OCULAR NEOVASCULARIZATION. 
[This chapter forms the following submitted manuscript: 
Halesha D. Basavarajappa, Rania S. Sulaiman, Xiaoping Qi, Bit Lee, Judith 
Quigley, Kamakshi L. Sishtla, Sameerah Alkhairy, Kamna Gupta, Buyun Tang, 
Mehdi Shadmand, Maria B. Grant, Michael E. Boulton, Seung-Yong Seo & 
Timothy W. Corson. Ferrochelatase is a therapeutic target for ocular 
neovascularization, submitted]. 
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5.1. CHAPTER SUMMARY 
Using a forward chemical genetic approach to find targets of 
cremastranone, we identified the heme synthesis enzyme ferrochelatase (FECH) 
as necessary for angiogenesis in vitro and in vivo. FECH is overexpressed in wet 
AMD eyes and murine choroidal neovascularization; knockdown modulates 
endothelial nitric oxide synthase function and VEGF receptor levels. FECH is 
inhibited by the approved oral antifungal drug griseofulvin, and this compound 
ameliorated choroidal neovascularization in mice when delivered intravitreally or 
orally. Thus, FECH inhibition could be used therapeutically to block ocular 
neovascularization. 
5.2. INTRODUCTION 
To uncover novel, potentially druggable angiogenesis mediators, here we 
took a forward chemical genetic approach to find protein targets of an 
antiangiogenic natural product (Sulaiman et al., 2014), cremastranone (Chapter 
3; Kim et al., 2007; Kim et al., 2008; Lee et al., 2014a; Shim et al., 2004). I 
identified ferrochelatase (FECH) as a target of this compound, and show that it is 
necessary for angiogenesis in vitro and in vivo and targetable with an FDA-
approved small molecule therapeutic. FECH is the terminal enzyme in heme 
biosynthesis, responsible for catalyzing the insertion of Fe2+ ion into 
protoporphyrin IX (PPIX) (Hamza and Dailey, 2012). To my knowledge, I 
describe here for the first time FECH’s role as a druggable mediator of 
angiogenesis. 
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5.3. MATERIALS AND METHODS 
5.3.1. Materials 
Details regarding the cell culture conditions, TUNEL assay reagents, 
Alamar blue assay, EdU Incorporation assay, in vitro matrigel assay and qRT-
PCR materials are already described in chapter 2 (Section 2.3.1). Monoclonal 
antibody against α-tubulin (DM1A), actin (AC40), protoporphyrin IX, 5-
aminolevulinic acid, hemin, hemin agarose beads, griseofulvin and L-arginine 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). N-methyl 
protoporphyrin (NMPP), the primary antibodies against FECH (A-3) and PDXK 
(F-12) were obtained from Santa Cruz (Santa Cruz, CA, USA). Antibodies 
against cleaved caspase 3 (5A1E), phospho-VEGFR2 (Tyr 1175) (19A10), 
phospho-eIF2α (Ser 51) (119A11), eIF2α and eNOS (49G3) were from Cell 
Signaling (Danvers, MA, USA). Anti-HIF-1α (241809) antibodies were purchased 
from R&D systems (Minneapolis, MN, USA). Secondary antibodies were from 
Thermo Fisher Scientific (Pittsburgh, PA, USA). 4,5-Diaminofluorescein diacetate 
(DAF-2 diacetate) was purchased from Cayman Chemicals (Ann Arbor, MI, 
USA). ECL Prime Western Blotting Detection reagent was purchased from GE 
Healthcare (Buckinghamshire, UK).  
5.3.2. Preparation of photoaffinity reagents 
Synthesis and characterization of affinity reagents 16 and 17 will be 
reported elsewhere (Lee et al., submitted). Compounds 1 and 4 were 
synthesized as described (Chapters 2 and 3). For pulldowns, Neutravidin 
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agarose beads (1 mL of 50 % slurry) were washed three times in buffer A 
containing 25 mM Tris-HCl pH 7.4, 150 mM NaCl, 2.5 mM sodium 
pyrophosphate, 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.1 mM sodium 
orthovanadate, 10 µg/mL aprotinin and 10 µg/mL leupeptin. The beads were then 
incubated with 100 µM affinity or control reagents 16 or 17 overnight at 4°C with 
rotation. The beads were blocked using 1 mM biotin solution prepared in buffer A 
for 1 hour followed by incubation with 1 mg/mL cytochrome c solution for 1 hour 
at 4°C. The beads were then washed three times with buffer A and resuspended 
in 1 mL. 
5.3.3. Photoaffinity pull down experiments 
Flash-frozen porcine brain (20 g) obtained from the Purdue-Indiana 
University School of Medicine Comparative Medicine Program was homogenized 
in 50 mL Buffer A using a tissue homogenizer. The homogenate was centrifuged 
at 2000×g for 5 minutes. The supernatant (S1) was then dounced 50 times 
followed by 10 min sonication with amplitude of 60% in cycles of 10 sec 
sonication on and 40 sec sonication off (Q125 from QSonica, Newtown, CT, 
USA). The lysate was then centrifuged at 11,000xg for 30 min. The resulting 
supernatant (S2) and pellet (P2) fractions were both collected. The P2 pellet was 
resuspended in buffer B: 1% Triton X-100 + buffer A and then dounced 25 times 
and centrifuged at 11,000xg for 30 min; supernatant (S3) was collected. Both S2 
and S3 supernatants were equally divided and each fraction was incubated with 
500 µL photoaffinity or control reagent conjugated to Neutravidin beads for 75 
min at 4°C with shaking.  
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The beads were collected by centrifugation at 500×g for 5 min, then 
resuspended in 1 mL of buffer B and irradiated with 365 nm UV light (Mercury 
bulb H44GS100 from Sylvania in a Blak-Ray 100A long-wave UV lamp) in a 60 
mm Petri dish for 30 min at 4°C. The beads were then washed two times in buffer 
B, followed by three washes in high-salt buffer containing 25 mM Tris-HCl pH 
7.4, 350 mM NaCl, 1% Triton X-100 and 1 mM PMSF. The beads were then 
washed again in salt-free buffer containing 25 mM Tris-HCl, 1% Triton X-100 and 
1 mM PMSF. After 5 min incubation, the beads were collected and any residual 
liquid was removed using a Hamilton syringe. The Neutravidin beads were then 
boiled in 300 µL of 2× SDS-PAGE gel loading dye containing 30 µL of 2-
mercaptoethanol for 10 min at 70°C to release the bound proteins. After boiling, 
the contents were allowed to cool and after a quick spin the eluate was collected 
using a Hamilton syringe.  The eluates were then analyzed in 4–20% gradient 
SDS-PAGE and the protein bands were visualized using silver staining (Corson 
et al., 2011). The protein bands pulled down specifically by photo-affinity reagent 
were excised from the silver stained SDS-PAGE gel and analyzed by mass 
spectrometry (IUSM Proteomics Core). Using SequestTM algorithms and the 
swine database (UniProt), the identities of the pulled down proteins were 
confirmed (Fig. 5.2).  
For competition experiments, S2 and S3 supernatants were incubated 
with affinity reagent-Neutravidin beads in the presence of 1 mM of 
cremastranone isomer SH-11052 (2) (Chapter 2) and then processed as 
described above. 
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5.3.4. Recombinant FECH 
Recombinant human FECH protein was purified as described previously 
(Dailey et al., 1994). Briefly, Escherichia coli JM109 cells transformed with 
plasmid pHDTF20 encoding recombinant human FECH were grown in 
Circlegrow medium containing 100 µg/mL ampicillin for 20 hours at 30°C. The 
cells were harvested and resuspended in solubilization buffer (50 mM Tris-MOPS 
pH 8.0, 1% sodium deoxycholate, 100 mM KCl and 1 mM PMSF). The cell 
suspension was sonicated and then ultracentrifuged at 45000xg for 30 min. The 
supernatant was subjected to cobalt-affinity chromatography and the column was 
washed with solubilization buffer containing 20 mM imidazole. The protein was 
eluted with 250 mM imidazole in solubilization buffer. The protein eluate was then 
dialyzed in solubilization buffer containing 10% glycerol before storage at 4°C. 
Recombinant protein (200 µg) was used in pulldown experiments as above. 
5.3.5. Immunoblot assay 
Immunoblots were performed as described previously in chapter 2 
(Section 2.3.9). Proteins were immunoblotted with antibodies against FECH 
(1:1000 dilution), α-tubulin (1:1000 dilution), phospho-VEGFR2 (1: 500), 
VEGFR2 (1:500), phspho-eIF2α (1:500), eIF2α (1:500), HIF-1α (1:500), actin 
(1:1000)  and eNOS (1:500 dilution). All of the dilutions were made in Tris 
Buffered Saline-0.05% Tween-20 buffer containing 2% bovine serum albumin 
(BSA).  
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5.3.6. siRNA knock down of FECH in cells 
Cells were grown in 6-well plates until 80% confluency was achieved. 
Then 7.5 µL of Lipofectamine RNAiMAX reagent (Life Technologies) mixed with 
30 pmol of siRNAs was added to each well according to the protocol 
recommended by the manufacturer. For FECH knockdown, 15 pmol each of two 
siRNAs (SASI_Hs01_00052189 and SASI_Hs01_00052190; Sigma) and for 
PDXK knockdown, 30 pmol of siRNA (SASI_Hs01_00053806) were used and for 
negative control, MISSION® siRNA Universal negative control was used. Fresh 
EGM-2 medium was added to the plate 24 hours after transfection and cells were 
used 48 hours after transfection for further experiments except for the 
proliferation time course, for which 24 hours after transfection the cells were 
trypsinized and seeded in a 96-well plate.  
5.3.7. Cell proliferation assay 
Proliferation of cells was monitored as described in chapter 2 (Section 
2.3.2). The concentration ranges of griseofulvin and NMPP used were 0.5 nM – 
500 µM and 0.1 nM – 100 µM respectively. 
5.3.8. Migration assay 
The migration of HRECs was monitored as described in chapter 4 
(Section 4.3.7). 
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5.3.9. In vitro Matrigel tube formation assay 
The ability of HRECs to form tubes in vitro was monitored as described in 
chapter 2 (Section 2.3.4). 
5.3.10. Animals 
All animal experiments were approved by the Indiana University School of 
Medicine Institutional Animal Care and Use Committee and followed the 
guidelines of the Association for Research in Vision and Ophthalmology 
Statement for the Use of Animals in Ophthalmic and Visual Research. Wild-type 
female C57BL/6J mice, 6–8 weeks of age or timed pregnancies, were purchased 
from Jackson Laboratory (Bar Harbor, ME) and housed under standard 
conditions(Wenzel et al., 2015). Mice were anesthetized for all procedures by 
intraperitoneal injections of 17.5 mg/kg ketamine hydrochloride and 2.5 mg/kg 
xylazine.  
5.3.11. L-CNV model  
L-CNV was generated as described previously (Lambert et al., 2013; Poor 
et al., 2014; Sulaiman et al., 2015). Briefly, eyes were dilated using 1% 
tropicamide, then underwent laser treatment using 50 µm spot size, 50 ms 
duration, and 250 mW pulses of an ophthalmic argon green laser, wavelength 
532 nm, coupled to a slit lamp. Where indicated, intravitreal injections of PBS 
vehicle, siRNA (1.25 µM final intravitreal concentrations) or griseofulvin (50 µM, 
100 µM, final intravitreal concentrations) were given in a 0.5 µL volume at time of 
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laser treatment. Eyes were numbed with tetracaine solution before the injection, 
and triple antibiotic ointment was used immediately after the injection to prevent 
infection. A masked researcher undertook imaging and analysis to avoid bias. 
One week after laser treatment, mice underwent optical coherence tomography 
using a Micron III imager (Phoenix Research Labs, Pleasanton, CA, USA) and 
CNV lesions were quantified as ellipsoids as described(Sulaiman et al., 2015). 
Two weeks after laser treatment, eyes were enucleated and fixed, choroidal 
flatmounts prepared, and vasculature stained with rhodamine labeled Ricinus 
communis agglutinin I (Vector Labs, Burlingame, CA, USA), followed by confocal 
Z-stack imaging (LSM 700, Zeiss, Thornwood, NY, USA) to estimate lesion 
volume. 
5.3.12. Immunostaining 
Human donor eyes were obtained from the National Disease Research 
Interchange (Philadelphia, PA) with full ethical approval for use in research. 
Mouse eyes were post induced laser-CNV for 14 days. The eyes were 
enucleated and fixed in 4% paraformaldehyde/PBS overnight. The anterior 
segment, lens, and vitreous were removed and the posterior eye cups were 
prepared for standard paraffin sections or retinal flat mounts. Deparaffinized 
sections were treated with rodent deblocker (Biocare Medical, Concord, CA, 
USA) for antigen retrieval. The sections or flat mounts were washed with PBS 
then permeabilized with 0.3% Triton X-100 and nonspecific binding blocked by 
10% normal goat serum plus 1% BSA in PBS. They then received primary 
antibody (polyclonal anti-FECH (C20, Santa Cruz) at 1:500 for 16 hours at 4°C. 
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After primary incubation, tissues were washed and incubated for 1.5 hours at 
room temperature with secondary antibody (Cy3 conjugated goat anti-rabbit IgG, 
1:600) at 4°C with 0.1% Triton X-100. We used a vascular specific dye (Ricinus 
Communis Agglutinin I; Vector Laboratories, Inc.) conjugated to AlexaFluor 488 
to label retinal vasculature. This was incubated for 30 minutes at room 
temperature in 1:400 of 10 mM HEPES plus 150 mM NaCl and 0.1% Tween-20. 
After washing, specimens were mounted in aqueous mounting medium 
(VectaShield; Vector Laboratories, Inc.) and coverslipped for observation by 
confocal microscopy. All microscopic images were acquired with identical 
exposure settings. 
5.3.13. Choroidal sprouting assay 
Choroidal sprouting was assessed as described (Sulaiman et al., 2016). 
Briefly, pieces of choroid-sclera dissected from euthanized mouse eyes were 
embedded in Matrigel and grown in EGM-2 medium plus antibiotics for 72 hours 
to allow sprouting to initiate. The indicated concentrations of griseofulvin (in 
DMSO, final DMSO concentration 1%) were added and growth allowed to 
proceed for 48 hours. Images were taken and growth quantified by measuring 
distance from the edge of the choroidal piece to the growth front in 4 directions 
per sample. 
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5.3.14. Griseofulvin Feeding 
Mice were fed griseofulvin for a total of 3 weeks, with chow changed every 
2-3 days. Standard mouse chow (5 g/mouse/day) was mixed in water (2.2 mL 
H2O/gram chow), soaked for 15 min, then mashed. Griseofulvin doses were 
prepared at 0.0% (control), 0.5%, and 1.0% with 0.0 g, 0.5 g, and 1.0 g 
griseofulvin : 10 mL corn oil : 100 g mouse chow ratio, respectively. Both 0.5% 
and 1.0% doses were expected to substantially inhibit Fech and induce a 
protoporphyria-like phenotype, based on previously published work(Holley et al., 
1990; Lochhead et al., 1967; Martinez et al., 2009). The corn oil solutions and 
mouse chow mixture were manually mixed thoroughly for 10 min. During 
treatment, the mice were examined and weighed 3 times/week (Fig. 5.11a). On 
Day 8, mice underwent L-CNV as above, and were imaged by OCT at Day 15 
and Day 22, at which time they were euthanized. The eyes were enucleated and 
flatmounts prepared as above. The livers were dissected out and weighed (Fig. 
5.11b). 
5.3.15. eNOS assay 
eNOS activity was measured in cells as described before (Räthel et al., 
2003). Briefly, HRECs (10,000 cells/well) were seeded in 96-well clear bottom 
black plates and incubated for 24 hours at 37°C and 5% CO2. Then cells were 
washed with PBS and incubated for 5 min at 37°C with 100 µL of 100 µM L-
arginine prepared in PBS. Subsequently, 100 nM of DAF-2 diacetate was added 
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to each well and fluorescence readings were taken at excitation and emission 
wavelengths of 495 nm and 515 nm respectively using the Synergy plate reader. 
5.3.16. Hemin pulldown 
HRECs were grown in EGM-2 medium in 10 cm plates until ~50% 
confluent. Cells were then treated with 10 µM NMPP or DMSO control for 1 
week. Medium was changed every 2 days with treatments added to the fresh 
medium every time. Cells were then lysed with NP-40 lysis buffer containing (20 
mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40, 20 µM leupeptin, 1 mM PMSF, 1 mM 
NaF, 1 mM β-glycerophosphate, 2 mM sodium orthovanadate, 2 mM EDTA, 10% 
glycerol) and then centrifuged at 14,000×g for 10 min at 4°C.  Supernatant was 
collected and samples were pre-cleared by incubation with Neutravidin beads for 
1 hour at 4°C followed by centrifugation at 500×g for 5 min at 4°C. supernatant 
was then collected and protein concentration was determined using a Bradford 
assay. Equal amounts of total protein (40 µg) from each sample were incubated 
with ~ 50 µl hemin agarose beads, pre-washed 3 times with lysis buffer, for 1 
hour at 4°C. 
The beads were then washed two times in NP-40 buffer, followed by two 
washes in high-salt buffer containing 20 mM Tris-HCl pH 8.0, 350 mM NaCl, and 
1 mM PMSF. The beads were then washed once with a very high-salt buffer 
containing 20 mM Tris-HCl pH 8.0, 500 mM NaCl, and 1 mM PMSF. The beads 
were then washed again in salt-free buffer containing 20 mM Tris-HCl and 1 mM 
PMSF. After 5 min incubation, the beads were collected and any residual liquid 
		 104 
was removed using a Hamilton syringe. The hemin agarose beads were then 
boiled in 30 µL of 2× SDS-PAGE gel loading dye containing 30 µL of 2-
mercaptoethanol for 10 min at 70°C to release the bound proteins. After boiling, 
the contents were allowed to cool and after a quick spin the eluate was collected 
using a Hamilton syringe. The eluates were then analyzed in 4–20% gradient 
SDS-PAGE and then transferred onto PVDF membranes. Proteins were 
immunoblotted with antibodies against α-tubulin (1:1000 dilution) and eNOS 
(1:500 dilution). All of the dilutions were made in Tris Buffered Saline-0.05% 
Tween-20 buffer containing 2% bovine serum albumin (BSA).  
5.3.17. PPIX build-up assay 
HRECs were grown in a 6-well plate until confluent. Then cells were 
serum starved overnight in EBM-2 medium. Fresh EGM-2 medium containing 
DMSO or compounds was added to cells and they were incubated at 37°C for 1 
hour followed by addition of 1 mM 5-ALA to increase flux through the heme 
biosynthetic pathway. After 3 hours of incubation in the dark at 37°C the cells 
were trypsinized and lysed in buffer containing 25 mM HEPES-NaOH pH 7.4, 
150 mM NaCl, 1% NP-40, 10% glycerol and 1 mM PMSF. The cell lysates were 
incubated in the dark at 4°C for 20 min on a shaker and centrifuged at 12000×g 
for 15 min. Supernatants were collected for analysis. In a 384-well black plate, 20 
µL of supernatant was mixed with 20 µL of 1:1 solution of 2 M perchloric acid and 
methanol. After 5 min of incubation, fluorescence readings were taken at 
excitation and emission wavelengths of 407 nm and 610 nm using the Synergy 
plate reader.  
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5.3.18. Iron chelation 
Compound or DMSO (1 µL) was incubated with 2.5 mM freshly prepared 
ferrous ammonium sulfate in a final volume of 100 µL for 5 minutes at 37°C. 
Then 100 µL of 2.5 mM ferrozine solution was added to the wells and 
spectrophotometric readings were taken at 562 nm using the Synergy plate 
reader. Decrease in absorbance readings at 562 nm represents iron chelation. 
5.3.19. Apoptosis assays 
Caspase-3 immunofluorescence and TUNEL assays were performed as 
described previously (Section 2.3.5 and Section 4.3.6, respectively).  
5.3.20. qRT-PCR 
The assay was performed as described previously in chapter 2 (Section 
2.3.8). Primer/probesets used were: FECH (Hs01555261_m1), HIF1A 
(Hs00153153_m1), NOS3 (Hs01574659_m1), VEGFA (Hs00900055_m1), 
VEGFR2 (Hs00911700_m1), and housekeeping controls GAPDH 
(Hs99999905_m1), HPRT (Hs02800695_m1), and TBP (Hs00427620_m1). The 
data were analysed using the ΔΔCt method. The expression levels of genes were 
normalized to the 3 housekeeping genes and calibrated to the negative siRNA-
treated sample. 
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5.3.21. Statistical analyses 
Both in vitro and in vivo data were analyzed using Student’s t-test or one-
way ANOVA with Dunnett’s or Tukey’s post hoc tests for comparisons between 
the groups as appropriate in GraphPad Prism 6 software. The choroidal 
sprouting assay was analyzed using repeated measures two-way ANOVA with 
Dunnett’s post hoc test. P-values of <0.05 were considered significant in all tests.  
5.4. RESULTS 
5.4.1. Ferrochelatase is a target of an antiangiogenic compound 
To identify potentially novel protein modulators of angiogenesis, we used 
photoaffinity chromatography to search for targets of the naturally occurring 
antiangiogenic compound, cremastranone (Fig. 5.1A), which has selective 
antiproliferative effects on endothelial cells (Chapter 3). Protein binding partners 
of cremastranone were pulled down from a tissue lysate using immobilized 
cremastranone-based affinity reagent but not a negative control reagent (Fig. 
5.1B). One of the two pulled down proteins was identified using peptide mass 
fingerprinting as FECH (Fig. 5.1C and Fig. 5.2) and the other as pyridoxal kinase 
(PDXK) (Fig. 5.2 and Fig. 5.3). Although knock down of PDXK inhibited 
proliferation and migration of HRECs, tube formation ability of HRECs was not 
inhibited (Fig. 5.3). Hence PDXK protein was not pursued further. 
Immunoblot of eluates from photoaffinity pull down experiments confirmed 
the identity of the other pulled down protein using an antibody against FECH 
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(Fig. 5.1D). In order to confirm specificity of binding between cremastranone and 
pulled down proteins, affinity reagent was incubated with tissue proteins in the 
presence of excess active cremastranone isomer SH-11052 (2) (Fig. 5.1B) 
(Chapter 2).  Under this condition, the binding of FECH to affinity reagent was 
markedly (87%) decreased, indicating competition for binding to FECH between 
the cremastranone isomer and the affinity reagent (Fig. 5.1E).  
Recombinant FECH also interacted with the affinity reagent (Fig. 5.1F, G), 
indicating that the interaction does not require eukaryotic accessory proteins.  
Some binding to the negative control is likely due to the abundance of 
recombinant protein present; recent work confirms that cellular FECH does not 
readily bind benzophenone linkers (Park et al., 2016). Moreover, cremastranone 
treatment of human retinal endothelial cells (HRECs) caused a dose-dependent 
buildup of PPIX (Fig. 5.5A), indicative of FECH inhibition, and addition of excess 
5-aminolevulinic acid (5-ALA; the first precursor compound in the heme 
biosynthetic pathway that promotes increased heme production) partially rescued 
cremastranone’s antiproliferative effects on HRECs (Fig. 5.5B). Cremastranone 
did not chelate iron, suggesting that it does not act indirectly on FECH by 
sequestering FECH’s Fe2+ substrate (Fig. 5.5C). The FECH pathway, therefore, 
is targeted by a known antiangiogenic compound, suggesting that this protein 
and pathway are important for angiogenesis. 
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Figure 5.1. Ferrochelatase (FECH) is a target of the antiangiogenic natural 
product, cremastranone. (A) Chemical structure of cremastranone (1) (top). 
Anti-proliferative activity of cremastranone (bottom) shown as the 50% growth 
inhibitory concentration (GI50) on human retinal endothelial cells (HRECs), 
human umbilical vein endothelial cells (HUVECs) and non-endothelial ocular 
cells (uveal melanoma 92-1, retinoblastoma Y79, and retinal pigment epithelium 
ARPE-19). (B) Structures of compounds used in photoaffinity chromatography. 
(C) Proteins pulled down with indicated reagents in photoaffinity chromatography 
were separated on SDS-PAGE and silver stained. (D) Immunoblot of pulled down 
proteins using antibody against ferrochelatase (FECH). (E) Immunoblot of pulled 
down proteins from competition assay with excess active cremastranone isomer 
(4); quantification of band intensity shown. (F) Silver stained SDS-PAGE gel of 
recombinant human FECH protein pulled down using photoaffinity 
chromatography. (G) Anti-FECH immunoblot of a similar pulldown experiment. All 
the gel and immunoblot images are representative from at least two independent 
experiments. 
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Figure 5.2. Peptide mass fingerprinting analysis of proteins pulled down 
with a cremastranone affinity reagent from a porcine brain lysate. 
 
 
Figure 5.3. Role of PDXK in angiogenesis in vitro. (A) Peptide mass 
fingerprinting analysis of proteins pulled down with a cremastranone affinity 
reagent. (B) Knock down of PDXK using siRNA as monitored by immunoblot. (C) 
Inhibition of proliferation and migration (D) of HRECs after treating with PDXK 
specific siRNA. (E) effect of knocking down PDXK in HRECs on tube formation 
ability as monitored by in vitro matrigel experiments. Graphs show mean±SEM, 
n≥3 samples. Representative results from at least 3 independent experiments. *, 
p<0.05; relative to negative siRNA controls. 
 
Accession Description Score Coverage # Unique Peptides # Peptides # PSMs
*
F1S1X4 Ferrochelatase (Fragment) OS=Sus scrofa GN=FECH PE=3 SV=2 - [F1S1X4_PIG] 62.5 34.4 9 9 59
P00761 Trypsin OS=Sus scrofa PE=1 SV=1 - [TRYP_PIG] 58.0 8.7 1 1 80
F1RUV5 Uncharacterized protein (Fragment) OS=Sus scrofa GN=PC PE=4 SV=2 - [F1RUV5_PIG] 27.0 5.7 3 3 25
I3LVD5 Actin, cytoplasmic 1 OS=Sus scrofa GN=ACTB PE=2 SV=1 - [I3LVD5_PIG] 26.9 14.7 3 3 16
I3LNT6 Uncharacterized protein OS=Sus scrofa GN=KRT77 PE=3 SV=1 - [I3LNT6_PIG] 21.7 3.8 2 2 24
I3LLY8 Uncharacterized protein OS=Sus scrofa GN=KRT79 PE=3 SV=1 - [I3LLY8_PIG] 18.8 4.5 1 2 7
F1SGI7 Uncharacterized protein (Fragment) OS=Sus scrofa GN=LOC100525745 PE=3 SV=2 - [F1SGI7_PIG] 18.2 3.9 1 2 5
F1SHC1 Uncharacterized protein OS=Sus scrofa GN=LOC100127131 PE=3 SV=1 - [F1SHC1_PIG] 12.8 5.6 2 2 5
* PSMs à Peptide Spectrum Match
A 
B C 
D E 
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5.4.2. Ferrochelatase is required for angiogenesis in vitro 
The role of FECH in angiogenesis has not previously been explored, 
despite strong evidence linking heme catabolism with angiogenesis (Dulak et al., 
2008). To determine if FECH plays a key role in angiogenesis, we knocked 
FECH down in HRECs using siRNA (Fig. 5.4A & 5.4B) and monitored key 
angiogenic properties of HRECs in vitro. FECH knockdown significantly reduced 
the proliferation of HRECs (Fig. 5.4C and Fig. 5.7A). There was also a significant 
decrease in migration of HRECs treated with FECH siRNA in a scratch wound 
assay (Fig. 5.4D). Further, knocking down FECH in HRECs completely abolished 
the tube formation ability of HRECs as monitored in a Matrigel assay (Fig. 5.4E). 
To confirm the knockdown results, we also tested if a known pharmacological 
inhibitor of FECH shows antiangiogenic properties in vitro. N-methyl 
protoporphyrin (NMPP), a competitive inhibitor of FECH activity (Cole and Marks, 
1984), also inhibited proliferation, migration and tube formation ability of HRECs 
in vitro (Fig. 5.4F-H). However, despite these potent antiproliferative effects, 
FECH knockdown and low-dose chemical inhibition were not associated with 
increased apoptosis of these cells (Fig. 5.7B-D), indicating a cytostatic rather 
than cytotoxic effect. Moreover, FECH knockdown did not inhibit proliferation of 
non-endothelial ocular cell lines 92-1 and ARPE-19 as well as macrovascular 
human umbilical vein endothelial cells (HUVECs) (Fig. 5.9), indicating that FECH 
inhibition is not associated with general cytotoxicity. Together, these experiments 
confirmed that FECH function is required for angiogenesis in vitro.  
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Figure 5.4. FECH is an essential protein for angiogenesis in vitro. (A & B) 
FECH is knocked down using specific siRNAs as confirmed by immunoblot. (C) 
Proliferation of HRECs was monitored in presence or absence of FECH specific 
siRNA. (D) Scratch-wound migration assay was performed with or without FECH 
knock down in HRECs. (E) Ability of HRECs to form tubes in vitro on Matrigel 
was monitored after knocking down FECH. The effect of NMPP, a specific 
inhibitor of FECH activity, on in vitro proliferation (F), migration (G) and tube 
formation (H) ability of HRECs was measured. Graphs show mean±SEM, n≥3 
samples. Representative results from at least 3 independent experiments. *, 
p<0.05; **, p<0.01; ***, p<0.001 relative to negative siRNA or DMSO controls. 
Scale bars = 1 mm. 
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Figure 5.5. Validation of cremastranone’s inhibition of FECH. (A) 5-ALA 
induced protoporphyrin (PPIX) buildup in HRECs after cremastranone treatment. 
*, p<0.05; **, p<0.01; ***, p<0.001 relative to no cremastranone control. (B) 
Partial rescue of cremastranone’s inhibition of HREC proliferation with 5-ALA, an 
inducer of heme biosynthesis. HRECs treated with DMSO only are shown as 
100% proliferation control. *, p<0.05 relative to cremastranone only. (C) 
Cremastranone does not bind iron as determined in an iron chelation assay; 
EDTA and deferoxamine are positive controls. Representative figures from at 
least three independent experiments. Graphs show mean ± SEM with n ≥ 3.  
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5.4.3. Ferrochelatase is upregulated during neovascularization 
Given the potent antiangiogenic effects of FECH knockdown we observed 
in culture, we then explored whether FECH is associated with neovascularization 
in vivo. We employed a mouse model of laser-induced choroidal 
neovascularization (L-CNV). This widely used model recapitulates some of the 
features of wet AMD (Montezuma et al., 2009). FECH was overexpressed in and 
around lesions during neovascularization in this model (Fig. 5.6A). More 
importantly, FECH expression was seen throughout the retinas of human wet 
AMD patients analyzed postmortem (Fig. 5.6B). In the subretinal layers including 
the choroid (the origin of neovascularization in wet AMD) expression was 
significantly increased compared to healthy eyes (Fig. 5.6C). 
5.4.4. Ferrochelatase is required for neovascularization in vivo 
Since FECH upregulation suggested a role for this protein in 
neovascularization in the living eye, we asked whether decreased FECH would 
inhibit this process. When L-CNV mice were treated intravitreally with Fech-
specific siRNA, there was a significant decrease in choroidal neovascularization 
as compared with both saline treated control mice as well as control non-coding 
siRNA treated mice (Fig. 5.6D, E). These in vivo experiments confirm the clinical 
relevance of FECH in neovascularization, and the value of targeting this enzyme 
to block this process. 
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Figure 5.6. FECH is an essential protein for angiogenesis in vivo. (A) Whole 
mount staining of L-CNV mouse choroid stained with an antibody against Fech 
(red) and with agglutinin (green) to label neovascularization. (B) Immunostaining 
of sections of eye sections from a wet AMD patient or an age-matched control 
using an antibody against FECH (red). The nuclei of cells are stained blue with 
DAPI. Retinal layers indicated: GCL, ganglion cell layer; INL, inner nuclear layer; 
ONL, outer nuclear layer. (C) Quantification of the staining intensity of subretinal 
FECH, where CNV occurs. (D) Whole mount staining of RPE/choroid isolated 
from L-CNV mice treated with Fech specific siRNA. The choroidal vasculature 
was stained with agglutinin conjugated with Alexafluor 555 (red). *, p<0.05 for 
comparisons indicated. Graphs show mean±SEM, n≥3 samples. Xiaoping Qi 
performed immunostaining and laser treatment, and assisted with analysis.  
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Figure 5.7. Effect of FECH-siRNA, NMPP and griseofulvin on HRECs in  
apoptosis assays. (A) Time course of the effect of FECH siRNA on proliferation 
of HRECs. The % proliferation calculated are with respect to proliferation with 
negative control siRNA. **,p<0.01 versus negative siRNA. (B) FECH knockdown 
does not induce apoptosis, as assessed by TUNEL (red). (C) FECH knockdown 
does not induce apoptosis, as assessed by activated caspase-3 immunostaining 
(red). (D) NMPP and (E) griseofulvin induce minimal apoptosis in HRECs at 
effective concentrations, as assessed by TUNEL assay. Staurosporine (SP) is 
positive control. Representative figures from at least three independent 
experiments. Graphs show mean ± SEM with n ≥ 3. Scale bars = 1 mm. 
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5.4.5. Ferrochelatase-targeting therapy treats neovascularization 
The FDA-approved antifungal drug, griseofulvin, has been in clinical use 
for over half a century (Petersen et al., 2014). The primary antifungal mechanism 
of this compound is as a microtubule inhibitor (Borgers, 1980). However, an 
unexpected off-target effect of this drug is inhibition of FECH (Brady and Lock, 
1992; Holley et al., 1990; Martinez et al., 2009). Griseofulvin alkylates the heme 
prosthetic group of cytochrome P450 in vivo, forming NMPP, the active site 
FECH inhibitor (Liu et al., 2015). Taking advantage of this phenomenon, we 
treated HRECs with griseofulvin and observed dose-dependent antiproliferative 
effects, inhibition of migration, and inhibition of tube formation (Fig. 5.8A–C) 
similar to those observed after FECH knockdown. The concentrations of 
griseofulvin needed to have effects were higher than those seen with NMPP (Fig. 
5.4F–H), likely due to incomplete alkylation of heme in griseofulvin-treated cells. 
However, this concentration (~10 µM or ~3.5 ng/mL) is 2.75 logs less than that 
attained in plasma during antifungal treatment of humans (1– 2 µg/mL) (Epstein 
et al., 1972), suggesting that efficacy in vitro can be achieved in a clinically 
attainable concentration range. Moreover, effective antiangiogenic 
concentrations of griseofulvin were not associated with apoptosis (Fig. 5.7E). 
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Figure 5.8. Chemical inhibition of FECH inhibits angiogenesis in vitro. The 
effect of griseofulvin, an FDA-approved drug that inhibits FECH activity, on 
proliferation (A), migration (B) and tube formation (C) ability of HRECs was 
monitored in vitro. (D) The mouse choroidal sprouting assay was used to 
further measure the antiangiogenic potential of griseofulvin in vitro.  *, p<0.05; 
***, p<0.001; ****, p<0.0001 relative to DMSO controls (one- or two-way 
ANOVA with Dunnett’s post hoc tests). Graphs show mean±SEM, n≥3 
samples. Representative results from at least 3 independent experiments. 
Scale bars = 1 mm. Rania Sulaiman did the mouse choroidal sprouting assay. 
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Figure 5.9. FECH knockdown has no significant effects on proliferation of 
other cell types. (A) ARPE-19 retinal pigment epithelial cells. (B) 92-1 uveal 
melanoma cells. (C) HUVECs. Graphs show mean ± SEM with n ≥ 3. 
Representative figures from three experiments are shown; ns, non-significant, 
Student’s t-test p>0.05.  
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Further, griseofulvin inhibited formation of microvascular sprouts in the 
choroidal sprouting assay, an ex vivo model of choroidal angiogenesis (Fig. 
5.8D).   
Spurred by these findings, we tested griseofulvin as a therapy for L-CNV. 
Ad libitum feeding of ≥0.5% (w/w) griseofulvin to mice has previously been 
demonstrated to induce inhibition of FECH (Brady and Lock, 1992). Excitingly, 
such oral treatment of L-CNV mice decreased neovascularization (Fig. 5.10A–C 
and Fig. 5.11); similar, dose-dependent results were seen when griseofulvin was 
intravitreally injected instead; this is the standard delivery route for existing anti-
VEGF agents (Fig. 5.10D-F). 
5.4.6. Ferrochelatase depletion decreases the VEGF receptor via eNOS 
In order to understand how FECH contributes to angiogenesis, we 
knocked down FECH in HRECs and monitored levels of endothelial nitric oxide 
synthase (eNOS), a key angiogenesis regulator that requires a heme cofactor for 
its activity to produce the proangiogenic molecule nitric oxide (NO) (Förstermann 
and Münzel, 2006). Immunoblot of HRECs treated with FECH siRNA showed 
significantly decreased levels of eNOS (Fig. 5.12A). Further, eNOS activity was 
decreased in FECH knockdown HRECs as compared to negative control siRNA 
treated cells (Fig. 5.12B). 
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Figure 5.10. Antifungal drug griseofulvin inhibits ocular neovascularization 
in vivo. Mice were fed ad libitum with 0.5% and 1% griseofulvin for one week 
prior to, and throughout CNV development. Choroidal neovascularization was 
monitored by OCT in vivo (A) and confocal imaging of CNV lesions ex vivo (B). 
The lesion volumes were measured from confocal images (C). The effect of a 
single intravitreal injection of griseofulvin at time of laser treatment on choroidal 
neovascularization in the L-CNV model as monitored by OCT (D) and confocal 
imaging of CNV lesions (E). The CNV lesion volumes were measured using 
confocal images (F); Anti-VEGF is a positive control antibody therapy. The 
graphs show mean ± SEM with n = 6 mice per group. *,p<0.05; ****,p<0.0001 
versus vehicle. Scale bars for OCT images and immunostained choroids are 100 
µm and 50 µm respectively. Sameerah Alkhairy, Kamna Gupta and Rania 
Sulaiman performed these experiments and analysis. 
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Figure 5.11. Oral griseofulvin’s systemic effects. (a) oral griseofulvin 
treatment did not significantly change mouse weights during the experimental 
timecourse. (b) griseofulvin increased liver weights as expected with these 
treatments, confirming drug intake and systemic metabolism. The graphs show 
mean ± SEM with n = 6 mice for each group. ***, p<0.001. Sameerah Alkhairy, 
Kamna Gupta and Rania Sulaiman performed these experiments and analysis. 
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Despite the overall decrease in eNOS levels, we observed that there was 
an accumulation of apo-eNOS lacking the heme co-factor, as demonstrated in a 
hemin pull down assay (Fig. 5.12C) when HRECs were treated with NMPP, the 
specific inhibitor of FECH activity. As nitric oxide, product of eNOS 
enzyme activity, causes stabilization of hypoxia inducible factor (HIF) 1α (Sandau 
et al., 2001), we also monitored levels of this key mediator of angiogenesis after 
knocking down FECH in HRECS. FECH knockdown decreased protein levels 
HIF-1α (Fig. 5.12D). 
As VEGF is a major proangiogenic stimulus, we then monitored key 
events of VEGF signaling after knocking down FECH. We observed a profound 
decrease in (activating) phosphorylation of the major VEGF receptor VEGFR2 as 
well as total VEGFR2 protein levels in FECH knockdown cells when cultured in 
basal medium containing VEGF165 as growth factor (Fig. 5.12E); production of 
VEGFA mRNA was unchanged (Fig. 5.13). The protein levels of eNOS and 
VEGFR2 were rescued after treating FECH knockdown cells with exogenously 
added hemin (a stable form of heme, the enzymatic product of FECH) (Fig. 
5.12E). The decreased protein levels after FECH knockdown were not due to 
general translational inhibition: there was no difference in phosphorylation levels 
of eIF-2α in FECH siRNA treated cells (Fig. 5.12F).  
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Figure 5.12. FECH depletion suppresses VEGFR2 via eNOS and HIF-1α. (A) 
Protein levels of eNOS were measured by immunoblot after knocking down 
FECH in HRECs. (B) Production of NO was monitored using diamino fluorescein- 
2 diacetate based fluorimetric assay. (C) Immunoblots from hemin pulldown 
assay using proteins extracted from HRECs treated with DMSO or 10 µM NMPP. 
(D) HIF-1α was measured by immunoblot after knocking down FECH in HRECs. 
(E) Protein levels of eNOS and phosphorylation of VEGFR2 at Tyr1175 in 
HRECs after treatment with negative control or FECH siRNAs and/or hemin (1 
µM) were monitored by immunoblotting. (F) Phosphorylation of eIF2α and protein 
levels of Hsp90 were measured by immunoblot after knocking down FECH in 
HRECs to test if general translation is inhibited. (G) Proposed model for FECH 
regulation of angiogenesis through eNOS, HIF-1α, and VEGFR2. The figures are 
representative from at least 3 independent experiments and the graphs show 
mean ± SEM with n = 3. *, p<0.05; ***, p<0.001 compared to negative siRNA 
control. 
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Figure 5.13. Effect of FECH knockdown on mRNA expression in HRECs. 
qRT-PCR analysis shows no decrease in VEGFA or HIF1A expression while 
NOS3 (eNOS) and VEGFR2 expression is decreased after FECH knockdown. 
Graph shows mean ± SD with n = 3 technical replicates for each group. 
Representative results of three independent experiments. 
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5.5. DISCUSSION 
Understanding the molecular events of pathological angiogenesis is key to 
developing novel therapeutics for neovascular eye diseases such as PDR, ROP 
and wet AMD. Currently, the drug pipeline for these diseases is dominated by 
anti-VEGF biologics (Kaiser, 2013). Even though these drugs have been 
successfully used to halt the progression of disease in wet AMD and PDR 
patients, there is a significant patient population (~30%) who are resistant to 
these treatments (Folk and Stone, 2010b; Prasad et al., 2010). Hence 
diversification of the drug pipeline with novel therapeutic agents with different 
mechanisms of action is required (Smith and Kaiser, 2014). Towards this end, we 
used a forward chemical genetics approach using an antiangiogenic natural 
product, cremastranone, to uncover new drug targets for angiogenesis.  
Using a series of biochemical, in vitro and in vivo studies we have 
determined that FECH is a key protein involved in ocular angiogenesis and it can 
be exploited for developing novel antiangiogenic drugs. A photoaffinity based 
chromatographic technique identified FECH as a protein binding partner of 
cremastranone. Although, like other natural products, cremastranone likely 
exhibits polypharmacology, it exerts its antiangiogenic activity at least partially 
through inhibition of FECH activity. 
Interestingly, FECH is a bona fide mediator of angiogenesis. Lack of 
FECH activity caused inhibition of angiogenesis both in vitro and in vivo. More 
importantly, only HREC proliferation was inhibited in vitro while other ocular cell 
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types tested did not show significant decreases in cell proliferation after FECH 
knock down. Even macrovascular HUVECs were not as profoundly affected by 
FECH depletion as the microvascular HRECs. These data reveal that retinal 
microvascular endothelial cells are particularly sensitive to FECH depletion. The 
lack of cytotoxic effects of FECH inhibition leads to consideration of FECH as a 
novel therapeutic target for ocular neovascular disease, possibly with minimal 
side effects. Supporting this latter assertion, in the genetic disease erythropoietic 
protoporphyria (EPP), FECH activity is markedly reduced, but EPP patients 
infrequently present severe symptoms apart from skin photosensitivity (Lecha et 
al., 2009). Neovascularization in EPP patients has not been studied extensively, 
although a single case report describes an ocular phenotype of idiopathic optic 
neuropathy in an EPP patient, not conclusively related to the disease (Tsuboi et 
al., 2007). 
Excitingly, we have shown that the FDA-approved antifungal drug and 
FECH inhibitor griseofulvin inhibited ocular angiogenesis in the L-CNV mouse 
model when administered orally. Griseofulvin has been used widely for over half 
a century to treat fungal infections and is taken orally, often for months or years 
(Liu et al., 2015; Petersen et al., 2014). An off-target side effect of this therapy is 
that griseofulvin causes the formation of NMPP, along with other alkylated 
porphyrins, primarily in the liver (Figure 5.14) (Liu et al., 2015). NMPP in turn acts 
as an active-site inhibitor of FECH (Cole and Marks, 1984). As with genetic loss 
of function of FECH, apart from skin photosensitivity, no other major, common 
side effects are reported with systemic griseofulvin treatment of humans (Elewski   
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Figure 5.14. Effect of Griseofulvin on FECH activity. Griseofulvin alkylates the 
heme prosthetic group of cytochrome P450 enzymes to form alkylated porphyrins 
including NMPP. These alkylated porphyrins then bind to the active site and 
inhibit the enzyme activity of FECH. 
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and Tavakkol, 2005; Grover et al., 2012). However, griseofulvin treatment has 
been very rarely linked to liver injury mainly due to cholestasis. Only 5 % of 
griseofulvin treated patients experienced elevation of serum aminotransferases, 
a sign of liver injury. Some patients experience skin rashes due to elevated levels 
of porphyrins in the blood. Nevertheless, these symptoms are mild in the majority 
of the patients.  
The fact that griseofulvin-fed mice showed decreased ocular 
neovascularization as compared to control mice is important as currently there 
are no oral drugs available for the treatment of ocular neovascularization. The 
current approved drugs (anti-VEGF biologics) are all delivered intravitreally. If 
side effects were manageable, an oral therapy would be appealing. However, 
since griseofulvin was also effective when delivered intravitreally, combination 
intravitreal therapies of this drug with anti-VEGF biologics are also an interesting 
possibility to increase efficacy and decrease side effects of existing treatments. 
Moreover, griseofulvin offers the promise of low-cost treatment if shown 
efficacious in clinical trials. There are also prospects for novel FECH inhibitors as 
therapy: we have developed cremastranone analogs such as SH-11037 that may 
also act through FECH (Chapter 4), and recently, the drugs vemurafenib 
(Savitski et al., 2014) and salicylic acid (Gupta et al., 2013), as well as a lipid-
derived probe (Niphakis et al., 2015) compound were all shown to bind to FECH, 
suggesting that this protein has many potential binding clefts and is therefore 
likely druggable with novel compounds.  
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FECH is the only known enzyme in humans to synthesize heme and any 
loss of activity of this enzyme might result in intracellular heme deficiency (Dailey 
et al., 2000). Heme serves as either a prosthetic group for many enzymes or as a 
signaling molecule regulating expression of genes involved in cell differentiation, 
proliferation and signal transduction (Mense and Zhang, 2006). FECH knock 
down decreased protein levels of eNOS, HIF-1α and VEGFR2, key players 
promoting angiogenesis, in HRECs. As eNOS is a heme dependent enzyme, 
FECH knock down directly affects the stability and activity of eNOS enzyme. 
Nitric oxide (NO), product of the eNOS enzyme, induces angiogenesis, (Ziche 
and Morbidelli, 2000) partly by stabilizing HIF-1α under normoxia (Sandau et al., 
2001). This explains the logic behind the decreased protein levels of HIF-1α in 
FECH knock down cells with decreased eNOS activity. HIF-1α is a transcription 
factor, which regulates the expression of a range of proangiogenic proteins. 
VEGFR2, the major tyrosine kinase receptor of VEGF165, is up-regulated under 
hypoxia (Takagi et al., 1996; Tuder et al., 1995), So the decreased levels of 
VEGFR2 in HRECs after FECH siRNA treatment can be linked to decreased 
HIF-1α. Thus low protein levels of VEGFR2 (and thus angiogenesis) in FECH-
deficient HRECs can be directly attributed to loss of heme in cells and the 
resultant decrease in levels of eNOS enzyme (Fig. 5.12g). VEGFR2 depletion in 
turn further suppresses eNOS levels. The rescue of VEGFR2 and eNOS 
expression by addition of exogenous hemin, a stable form of heme, further 
supports this mechanism.  
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Our findings reveal a previously undocumented, central role of FECH in 
ocular angiogenesis. They provide a rationale for clinical testing of griseofulvin in 
neovascular eye disease. In addition, it will be valuable to develop novel, FECH-
targeted therapies for treating the debilitating ocular diseases caused by 
neovascularization.  
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CHAPTER 6. DISCUSSION 
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6.1. OVERALL SUMMARY 
The primary goal of this study was to understand how cremastranone 
inhibits ocular angiogenesis by identifying the cellular proteins (targets) with 
which it interacts and then elucidating the role of the target proteins in 
angiogenesis. This work encompassed confirming the antiangiogenic activities of 
synthetic cremastranone 1 and its analogues SH-11052 (2) and SH-11037 (14a), 
establishing the SAR of cremastranone and investigating the role of a 
cremastranone target protein, FECH in ocular angiogenesis (Fig. 6.2).  The 
novelty of this research work is the identification of SH-11037 (compound 14a) as 
a highly specific inhibitor of ocular angiogenesis and the discovery of FECH as a 
key mediator of ocular angiogenesis. I have not come across any small molecule 
that is very selective against HRECs compared to HUVECs and other ocular 
non-endothelial cells. This is a significant achievement as it enables us to pursue 
developing drugs which specifically inhibit ocular angiogenesis without affecting 
the normal vasculature and angiogenesis taking place elsewhere in the body.  
Here I will discuss the primary issues addressed in each chapter of my 
dissertation including how this work impacts the drug discovery program in the 
ocular angiogenesis field.   
SH-11052 (2) was synthesized during the preparation of cremastranone 
as a regioisomer. It differs from cremastranone only in the positions of its 
methoxy and hydroxyl groups on C-6 and C-7 of the chromanone ring. While the 
methoxy and hydroxyl groups positions are on C-6 and C-7 respectively in 
cremastranone, their positions are reversed in SH-11052 (Fig. 2.1). Nonetheless 
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this minor change significantly altered the potency of the compound and also the 
selectivity of the compound against non-endothelial cells. Cremastranone has 
nanomolar GI50 values against endothelial cells as compared to high micromolar 
GI50 values against non-endothelial ocular cell lines (Table 6.1). However this 
difference in selectivity and high potency disappeared by changing the positions 
of methoxy and hydroxyl groups on the A-ring in SH-11052, indicating the 
importance of these groups on the A-ring. However even though SH-11052 is 
less efficacious than cremastranone, it inhibited angiogenic abilities of HRECs 
and showed similar effects as cremastranone (inhibition of the TNF-α induced 
NF-κB pathway).  In addition synthesis of a scalable quantity of cremastranone is 
a significant achievement as it provided us enough material for performing 
mechanistic studies as well as opened new avenues to synthesize analogues 
with better potency and specificity.     
This work set the stage for establishing the SAR of cremastranone to 
identify new analogues, which are highly selective against HRECs and more 
potent than cremastranone. We chose to establish SAR of cremastranone using 
cell-based proliferation assays as the identity of cremastranone’s binding partner 
was not known and, also, employing both endothelial as well as non-endothelial 
cells for screening compounds helps us select compounds which are selective 
against endothelial cells, thereby minimizing the toxicity of lead molecules (Table 
6.1). In brief, SAR studies showed that an intact chromanone ring is crucial for 
activity and further modifications on the C-ring are well tolerated. In fact addition 
of bulkier groups on the C-ring increased potency as well as selectivity. 
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Figure 6.1. Overview of the mechanistic study of cremastranone. The 
objectives and key findings of each specific aim are described in black and green 
fonts respectively. 
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Towards this end, I identified SH-11037 as a potent and selective 
antiangiogenic molecule. It has GI50 values in low nanomolar concentrations 
against HRECs, 10-fold and >100-fold less potent against HUVECs and non-
endothelial ocular cell lines respectively (Table 6.1). This suggests that SH-
11037 could be a lead molecule for developing a drug, which is very specific 
against ocular angiogenesis without marked effects on normal vasculature as 
well as non-endothelial cells and thus minimizing the side effects of treatment. 
This is significant as current treatment options for ocular diseases arising from 
pathological angiogenesis are associated with significant acute systemic side 
effects, as noted (Chapter 1. Section 1.4.5). Further, I showed the ocular 
antiangiogenic activity of SH-11037 in preclinical studies in the OIR mouse model 
(Fig. 4.5). Subsequent work in our lab has shown that SH-11037 also inhibits 
angiogenesis in the choroidal sprouting assay ex vivo, impairs developmental 
angiogenesis in the eyes of zebra fish larvae and blocks choroidal 
neovascularization in the L-CNV mouse model. In mice, the antiangiogenic effect 
of SH-11037 was comparable to that obtained with anti-VEGF antibody and in 
addition SH-11037 synergized with anti-VEGF antibody both in vitro as well as in 
vivo. SH-11037 did not show any signs of ocular toxicity effects even at 100 µM 
concentration as there was no difference in the retinal function and retinal 
vasculature of mice treated with SH-11037 as compared to the placebo treated 
group (Sulaiman et al., 2016). 
Further SAR studies showed potential sites where long chemical linkers 
can be added to cremastranone derivatives, without affecting their biological 
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activities. Hence a benzophenone moiety connected to a chemical linker was 
added on the C-ring (Fig. 5.1). This linker was then connected to biotin. This 
whole complex reagent is termed an affinity reagent. Using this affinity reagent 
and a control reagent (Fig. 5.1), I identified FECH as a specific binding partner of 
cremastranone and then validated it in both in vitro and in vivo mouse models of 
angiogenesis. To my knowledge this is the first report describing the role of 
FECH in ocular angiogenesis.  
Table 6.1. GI50 values of cremastranone, SH-11052 and SH-11037 on various 
cell lines tested in AlamarBlue proliferation assay. 
Cell type SH-11052 Cremastranone SH-11037 
HREC 43 0.217 0.055 
HUVEC 18 0.377 0.75 
Y79 87 9.8 12 
92-1 6 47 >100 
ARPE-19 >100 >250 >100 
 
6.2 FECH OVERVIEW 
FECH is an inner mitochondrial membrane associated enzyme 
responsible for catalyzing the insertion of ferrous ion into protoporphyrin IX to 
form heme (Dailey et al., 2000). It is the terminal enzyme in the biosynthesis of 
heme (Figure 6.2). In humans the biosynthesis of heme starts with the 
condensation of glycine and succinyl-CoA to yield 5-aminolevulinic acid (ALA). 5-
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ALA is the sole contributor of the carbon and nitrogen atoms of heme.  Two 
molecules of 5-ALA are then condensed to yield a pyrrole molecule called 
porphobilinogen (PBG). Four molecules of PBG undergo oligomerization giving 
the linear tetrapyrrole molecule, 1-hydroxymethylbilane. Then ring closure 
happens to yield cyclic tetrapyrrole uroporphyrinogen III. The four acetic acid side 
chains of this cyclic tetrapyrrole undergo stepwise decarboxylation to form 
coproporphyrinogen III and oxidative decarboxylation yielding 
protoporphyrinogen IX. Subsequently oxidation of protoporphyrinogen leads to 
aromatization of the ring system to form protoporphyrin IX (PPIX). In the final 
step, insertion of ferrous ion leads to formation of the heme molecule (Layer et 
al., 2010). 
 The enzyme FECH was first reported in 1956 (Goldberg et al., 1956) and 
soon linked to the human genetic disease erythropoietic protoporphyria (EPP) 
(Dailey et al., 2000; Gouya et al., 1999). In humans a genetic defect that causes 
reduction in ferrochelatase activity results in EPP. There are over 30 different 
EPP mutations reported in the human genomic FECH gene which cause 
reduction in FECH activity (Rufenacht et al., 1998). Of these mutations, 18 are 
missense mutations and six are different exon deletions (exons 3, 4, 5, 7, 9, and 
10). Interestingly only two mutations (Y191H and P192T) are located in the active 
sites and the rest are scattered throughout the protein. In EPP, free 
protoporphyrin, mainly from erythropoietic tissues, is found to accumulate in the 
skin resulting in photosensitivity. The disease is not usually life threatening but 
causes irritation and pain upon exposure to sunlight as protoporphyrins are light 
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sensitive. Protoporphyrins absorb light and are converted to free radicals, which 
then damage the cell membrane and proteins. Only in 5 % of the EPP patient 
population, protoporphyrin accumulates, crystallizes and blocks biliary passages. 
In very few cases liver failure with cirrhosis may develop. But for the majority of 
EPP patients the condition is non lethal. However there are no extensive studies 
on EPP patients with respect to ocular diseases associated with pathological 
angiogenesis.  
Mammalian FECH is a nuclear encoded protein that is synthesized in the 
cytoplasm in a precursor form and then undergoes proteolytic posttranslational 
modification to remove the N-terminal organellar targeting sequence while being 
transported to the inner mitochondrial membrane (Dailey et al., 1994; Karr and 
Dailey, 1988). The molecular weight of monomeric mature human FECH is 43 
kDa. Human FECH is a homodimer with each monomer containing an active site 
and a [2Fe-2S] cluster. Some EPP mutations in FECH result in the enzyme not 
having an intact [2Fe-2S] cluster and loss of this feature results in loss of enzyme 
activity. Both [2Fe-2S] clusters are located at the dimer interface and are 
required for dimerization of FECH. However the importance of dimerization in the 
physiological functions of FECH is not yet understood (Dailey et al., 2000). 
The gene encoding FECH is located on chromosome 18q21.3 and is 
composed of 11 exons covering a region of approximately 45 kbp. The promoter 
region lacks both TATA and CAAT box motifs but contains CpG islands. Also, the 
FECH promoter contains two HIF-1 binding motifs suggesting that the expression 
of FECH is modulated by hypoxia, a strong stimulus for angiogenesis.  
		 139 
Only one gene encodes FECH in humans in all the cells even though the 
expression pattern of FECH is different in different cells. FECH is upregulated in 
erythroid cells to cope with the production of heme while in other cells its 
expression is low to provide housekeeping functions. This transcriptional 
regulation as well as the translational regulation of FECH in different cells is not 
clearly understood. There are some reports of the FECH gene being 
transcriptionally regulated by HIF-1 α, HNF-1α and FKLF-2, a Krüppel-like 
transcription factor (Asano et al., 2000; Liu et al., 2004; Muppala et al., 2000).  
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Figure 6.2. The heme biosynthetic pathway in mammals. 
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6.3. ROLE OF FECH IN ANGIOGENESIS 
Apart from its iron insertion activity, no other function has been assigned 
to FECH. Hence it becomes interesting to understand how FECH affects 
angiogenesis. One potential clue for the link between FECH and angiogenesis 
comes from a diagnostic as well as a treatment procedure called photodynamic 
therapy (PDT) wherein an analogue of PPIX, substrate of FECH, is accumulated 
specifically in growing endothelial cells. This endothelial-specific accumulation of 
PPIX analogue has been exploited to destroy neovessels.  
Recently, Inoue et al. (2013) showed that PDT involves an antiangiogenic 
mechanism in urothelial carcinoma and the efficacy of the treatment can be 
enhanced by inhibition of FECH. PDT involves administration of photosensitizers, 
including porphyrins such as verteporfin (trade name Visudyne) into the body and 
then irradiating with light of a particular wavelength (689 nm for Visudyne) to 
activate the photosensitizer. These activated photosensitizers produce reactive 
singlet oxygen and reactive oxygen species, which damage nearby cells. PDT 
was extensively used for treatment of wet AMD and is still being used in certain 
conditions of wet AMD and in cancer treatments. For some unknown reasons the 
administered photosensitizer selectively accumulates in growing blood vessels 
and hence PDT selectively kills neovessels. This concept is used in ALA-PDT 
wherein 5-ALA, a precursor and inducer of heme synthesis, is administered into 
the body. This results in accumulation of protoporphyrin IX in growing blood 
vessels via an unknown mechanism. This PPIX produces reactive oxygen 
species after exposure to light and selectively destroys growing blood vessels. 
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The only linkage between PDT and FECH is that the photosensitizer PPIX is a 
substrate of FECH and there are no extensive studies understanding why PPIX 
accumulates in growing blood vessels. Inoue et al studied the ALA-mediated 
PDT in the presence of deferoxamine (an iron chelator) to treat urothelial 
carcinoma in mice models and showed reduction in growth of abnormal blood 
vessels after ALA-PDT treatment in the presence of deferoxamine. Even though 
the group successfully provided proof of concept that PPIX selectively 
accumulates in growing blood vessels, the treatment strategy involving 
deferoxamine as a FECH inhibitor is debatable. Deferoxamine is an iron chelator 
and interferes with a wide range of biological reactions involving iron. Hence the 
improvement in efficacy of ALA-PDT observed in the presence of deferoxamine 
might not be due to FECH inhibition only. Thus selective accumulation of 
porphyrins in growing blood vessels needs to be studied in order to understand 
the role of FECH in angiogenesis. 
However during my dissertation work, the identification of FECH as a 
protein binding partner of cremastranone led me to the hypothesis that 
cremastranone might be acting by enhancing the accumulation of PPIX through 
inhibition of FECH. In support of this, there was an increase in PPIX levels after 
treatment with cremastranone. However since the majority of in vitro 
angiogenesis assays are carried out in dark conditions there should not be any 
photodynamic activation of PPIX and hence no cell death. Consistent with this, 
there was no induction of cell death as measured in apoptosis assays, when cells 
were treated with either cremastranone or FECH specific siRNAs (Fig. 5.7). This 
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led me to hypothesize that the product of FECH, heme, might play a role in 
angiogenesis either through a signaling pathway or as a crucial cofactor for 
proangiogenic molecules. There are wide varieties of enzymes, transporters, and 
receptors that use heme as a cofactor. Among these, I concentrated on 
endothelial nitric oxide synthase (eNOS) as it is a very well established 
proangiogenic molecule and needs heme for its stability and activity to produce 
nitric oxide (NO) (Rafikov et al., 2011). This is supported by the fact that apo-
eNOS is accumulated in HRECs treated with FECH specific inhibitor NMPP (Fig. 
5.6). NO is required for stabilization of HIF-1α under normoxic αconditions. HIF-
1α, in turn regulates expression of various angiogenic molecules including 
VEGFR2. Hence loss of FECH activity results in decreased protein levels of HIF-
1α and VEGFR2. Thus the overall angiogenic process is halted as a result of 
FECH inhibition. The importance of FECH in ocular angiogenesis is further 
substantiated by the fact that FECH is upregulated in wet AMD patient eyes and 
in choroidal neovascularized areas in L-CNV mouse eyes (Fig. 5.6). 
6.4. FECH INHIBITION AS A THERAPY 
Apart from the discovery of FECH as a key mediator of angiogenesis, 
another important finding of this study is the use of griseofulvin to inhibit 
choroidal neovascularization. The logic of choosing griseofulvin is that it 
undergoes metabolic conversion in liver by P450 enzymes to produce alkylated 
porphyrins including NMPP (Brady and Lock, 1992; Martinez et al., 2009). Thus, 
FECH activity is decreased in griseofulvin treated animals.  We observed that 
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choroidal neovascularization was significantly reduced in L-CNV mice that 
received griseofulvin either through oral or intravitreal administration as 
compared to placebo treated L-CNV mice. This is a significant observation as 
griseofulvin is already an FDA approved antifungal drug and it can be 
administered orally, unlike existing anti-VEGF biologics, which are injected into 
the eye. The toxicity, pharmacokinetic and pharmacodynamic properties of 
griseofulvin are very well studied so that minimal efforts are needed to take 
forward this drug to the clinical phase for treating wet AMD patients. As 
griseofulvin is available at cheaper costs as compared to the current anti-VEGF 
biologic drugs used, developing this drug for treating ocular diseases arising from 
pathological angiogenesis could result in a substantial decrease in cost of 
treatments for wet AMD, PDR and ROP patients. 
6.5. EXPERIMENTAL APPROACH 
Knowing the cellular targets of cremastranone is helpful if the process of 
developing antiangiogenic drugs is to be made more efficient. Natural products 
often interact with several proteins in cells. For drug discovery, an understanding 
of both protein functions and drug selectivity is highly important. Identification of 
the full spectrum of targets associated with cremastranone can lead to faster 
optimization of cremastranone, its effective clinical application as well as 
understanding of off-target side effects and thereby minimizing the possible 
toxicities early on in the drug discovery process. 
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Target identification is traditionally approached using a variety of genetic 
and biochemical methods such as yeast three hybrid systems, mammalian three-
hybrid system, phage display, protein microarrays and affinity chromatography 
(Schenone et al., 2013; Sleno and Emili, 2008). Each of these techniques has 
been successfully used to identify target proteins of bioactive small molecules. Of 
all these techniques I choose affinity chromatography technique, as it is a cost 
effective and unbiased direct approach of finding target proteins. However some 
of the drawbacks of this technique are that it can yield non-specific proteins, it 
requires a large amount of protein to start with and requires synthesis of affinity 
reagents. Despite these drawbacks this was an ideal approach available to us as 
we have a synthetic chemist collaborator who could synthesize the affinity 
reagent. 
This technique can yield a full spectrum of target proteins with which 
cremastranone interacts and thereby allows evaluation of polypharmacology. 
Moreover this method also allows small molecules to interact with 
posttranslationally processed, mature proteins under physiologically relevant 
conditions. I used a slight variation of the affinity approach, photo-affinity based 
chromatographic technique. The principle of the assay is that the affinity reagent 
is immobilized on agarose beads by exploiting strong binding affinity of avidin 
and biotin. The benzophenone moiety helps in covalently “locking” the target 
proteins bound to affinity reagent upon exposure to UV light. The cremastranone 
moiety of affinity reagent interacts with target proteins and upon exposure to UV 
light, because of proximity of target protein and benzophenone moiety in affinity 
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reagent, both target protein and affinity reagent are locked in covalent bonds. 
Then the immobilized protein-affinity reagent complex is extensively washed to 
remove non-specifically bound proteins. Bound proteins were eluted from 
matrices and separated by SDS-PAGE. The protein bands specifically eluted 
with the affinity reagent are digested with trypsin and the resulting peptides are 
analyzed by the LC-MS technique. This is one of the most direct and unbiased 
approaches for identifying drug targets. However the targets identified might not 
be the physiologically relevant targets through which cremastranone exerts its 
antiangiogenic activity. Hence, target validation becomes important. In target 
validation, we have to ensure that the identified target plays a crucial role in 
angiogenesis and decrease or increase of the levels of target protein in HRECs 
affects the angiogenic ability of HRECs. 
 To validate FECH as a target, I choose both an siRNA-based approach 
and a specific chemical inhibitor of FECH. This is because I observed inhibition 
of FECH activity in HRECs by cremastranone. Hence I hypothesized that FECH 
loss might decrease the angiogenic ability of HRECs. In order to achieve this I 
first followed an siRNA-based approach, as it is very specific for a gene and the 
success of the experiments can be analyzed by monitoring the protein levels of 
FECH using WB technique. Hence, siRNA-based approach gives direct answers. 
The reason I chose HRECs for all the in vitro angiogenic assays is that 
there is a high degree of heterogeneity in endothelial cell behavior. Endothelial 
cells differ in their physiological functions and response to stimuli in different 
organs and also between different tissues in order to adapt to the local needs. 
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HRECs are retinal endothelial cells, which are responsible for retinal 
neovascularization in the human eye and thus they are perfect in vitro cellular 
models for ROP and PDR. However there are no readily-available cell lines or 
primary cells to represent human choroidal neovascularization. I used both 
HRECs and HUVECs during SAR studies to identify molecules that are selective 
against HRECs as any molecule targeting HUVECs (macrovascular endothelial 
cells) might affect general vasculature in the body. The selectivity of SH-11037 
against HRECs again substantiates the fact that endothelial cells from different 
tissues behave differently. Hence HRECs are a convenient in vitro cell model for 
studying ocular angiogenesis in vitro. 
To monitor angiogenic properties of HRECs I chose proliferation, 
migration and Matrigel-based tube formation assay. During sprouting endothelial 
cells undergo cell division and hence monitoring proliferation of HRECs is critical. 
I used the alamar blue based method for measuring proliferation of HRECs as it 
is reliable, simple, inexpensive and adaptable to high throughput screening 
(Rampersad, 2012). The principle of the assay is that NADH dehydrogenases 
reduce resazurin (nonfluorescent) to resorufin (fluorescent). Using this method a 
large number of compounds can be screened to identify potential antiangiogenic 
molecules. Once potential candidates were selected then EdU incorporation 
assay was used to confirm the antiproliferative activities of potential 
antiangiogenic candidates. Thus using two different proliferation techniques gave 
us a fail-safe approach to identify antiangiogenic candidates.  
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Once the antiproliferative activity of compounds were confirmed then the 
migration ability of HRECs was tested in presence of compounds. For this, I used 
the scratch wound assay. This is an inexpensive, two-dimensional in vitro assay 
and cell migration can be monitored over time (Liang et al., 2007). An alternative 
migration assay is the ‘transfilter assay’, a modification of the Boyden chamber 
assay. The transfilter assay is a three-dimensional assay based on migration of 
endothelial cells towards the chemo-attractant (in this case VEGF) from one 
chamber to another chamber separated by a filter coated with ECM proteins such 
as collagen or fibronectin. This assay has several advantages including high 
sensitivity, high reproducibility, short duration (4-6 h). However it is expensive 
and scratch wound assay gives as much information as transfilter assays 
regarding the ability of test compounds to inhibit migration of endothelial cells in 
vitro (Goodwin, 2007; Liang et al., 2007). Hence the scratch wound assay was 
used in the project. 
 Assays that simulate the formation of capillary-like structures are 
regarded as representative of later stages of angiogenesis (differentiation). The 
Matrigel-based tube formation assay is a widely used technique for measuring 
tube formation ability of HRECs. This assay measures attachment, migration and 
differentiation of endothelial cells into tubule like structures in a manner that 
simulates the in vivo situation. Matrigel is a mixture of extracellular and basement 
membrane proteins derived from the mouse Engelbreth-Holm-Swarm sarcoma. 
Matrigel is the most potent matrix for tubule formation with tubules beginning to 
form in 1 h and completely formed within 12h following endothelial cell plating. 
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This assay can be easily adapted to 96-well plate format and free software 
plugins are available in ImageJ to process and analyze the images. This is a final 
confirmatory assay to determine the antiangiogenic activity of molecules in vitro 
(Arnaoutova and Kleinman, 2010; Goodwin, 2007). 
In order to monitor antiangiogenic activity of small molecules or FECH-
specific siRNAs, L-CNV and OIR mouse models were used to represent 
choroidal neovascularization (CNV) and retinal neovascularization (RNV) 
respectively. These two mouse models are standard models recapitulating the 
majority of the events of wet AMD and ROP respectively (Smith et al., 1994; 
Tobe et al., 1998). These two models are widely used to develop antiangiogenic 
molecules for treating ocular diseases and are highly reproducible.  
The L-CNV mice model uses breaking of Bruch’s membrane using an 
argon laser. In this model three laser burns are introduced in each eye and the 
antiangiogenic agent is injected into the eye. After 14 days the choroidal layer is 
removed and confocal images of the blood vessel stained choroids are taken and 
analyzed. This model has become the standard model to evaluate the 
antiangiogenic potential of pharmacologic therapies of CNV. The model can be 
used to assess gene therapy, siRNA targeting, novel delivery platforms and AAV 
mediated transfections. The L-CNV mouse model is relatively simple to create, 
inexpensive, reproducible, efficient and less time consuming than transgenic 
(VEGF164RPE65, Ccr2/Ccl2 deficient, ApoE overexpression) and knock out  
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(Cp-/- Hep-/Y) mice models (Grossniklaus, 2010). The model could also be used 
with transgenic mice such as Fech mutated mice to assess the pathobiology of 
CNV under decreased FECH activity. Also, CNV can be monitored using an OCT 
technique without killing the mice. Disadvantages of the model are that the model 
is artificial in nature and (unlike humans) mice do not have a macula. Despite this 
L-CNV is the standard animal model of CNV for most treatment evaluations. We 
used L-CNV model to test if FECH inhibition can be exploited to block choroidal 
neovascularization as seen in cell-based models. As expected, administration of 
siRNAs specific to FECH inhibited choroidal neovascularization. The same model 
was also used to confirm that chemical inhibition of FECH by griseofulvin leads to 
blocking of choroidal neovascularization. 
In the OIR mouse model pups are placed in an oxygen chamber (75 % 
O2) from P7 to P12, then brought back to normal room conditions (21 % O2) and 
injected with antiangiogenic agents on P12. The mice pups are sacrificed on P17 
and retinal whole mounts are stained for blood vessels and neovascularization is 
manually counted. This model is the standard animal model to assess 
pharmacological treatments. The neovascular response in the model is very 
consistent, reproducible and quantifiable. The major disadvantage of this model 
is the fact that central retinal vessels, rather than peripheral retinal vessels, are 
obliterated during hyperoxic exposure. This is different from what happens in 
ROP where the peripheral retinal vessels fail to develop. Despite this key 
difference, the mouse OIR model very closely recapitulates the pathologic events 
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of ROP. Using this model I could establish that compound SH-11037 inhibited 
ocular angiogenesis in vivo. 
In summary, I have used different techniques ranging from purified protein 
based affinity chromatography to cell-based in vitro approaches to animal based 
in vivo techniques. All of these techniques helped me develop SAR for 
cremastranone, selecting a novel and specific ocular antiangiogenic molecule 
SH-11037 and confirming the role of FECH in ocular angiogenesis both in vitro 
as well as in vivo. 
6.6. POTENTIAL LIMITATIONS OF THE STUDY 
Photo-affinity based pull down approach was the basis for identification of 
targets of cremastranone and the assumption was that the technique pulls down 
many target proteins considering the polypharmacology of natural products. I 
optimized the pull down approach and repeatedly pulled down FECH as one of 
the specific target proteins along with pyridoxal kinase (PDXK) enzyme in at least 
three independent experiments. However I didn’t find any other proteins pulled 
down with the affinity reagent, suggesting either the affinity between affinity 
reagent and other target proteins was weak or there was insufficient UV-cross 
linking. In both cases the loosely bound proteins would have been washed off 
during rigorous washing steps. Thus FECH might not be the only target through 
which cremastranone exerts its antiangiogenic activity. I pursued FECH as during 
the target validation FECH was confirmed to be a specific binding partner of 
cremastranone and FECH inhibition by siRNA inhibited the angiogenic abilities of 
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HRECs. Although knock down of PDXK enzyme inhibited the ability of HREC 
proliferation and migration there was no effect on tube formation ability HRECs in 
vitro (Fig. 5.3). Hence PDXK was not pursued further for mechanistic studies. 
Moreover for protein source I used porcine brain as the protein amount 
recovered from large scale HREC culturing was minimal, and growth was 
expensive. Even though I have established that cremastranone inhibits FECH 
activity in HRECs, it is possible that cremastranone can interact with other 
proangiogenic proteins specifically in HRECs and modulate their function. 
Nonetheless identification and validation of FECH itself is a novel work in ocular 
angiogenesis biology. 
Another limitation of the study is the choice of ocular non-endothelial cell 
lines used in proliferation assays. 92-1 and Y79 are uveal melanoma and 
retinoblastoma cell lines, respectively. They do not represent the normal, 
functional non-endothelial ocular cells. Only ARPE-19 represents the non-
transformed RPE cells of the eye and in future it would be useful to incorporate 
one or two more non-endothelial ocular cells which represent the cells of normal 
eye and are amenable for high-throughput proliferation assay.  
  
 
 
 
		 153 
6.7. FUTURE DIRECTIONS 
I identified FECH as a mediator of ocular angiogenesis and showed that 
loss of FECH activity results in decreased levels of eNOS, HIF-1α and VEGFR-2 
in HRECs. These findings further raise new questions regarding the functional 
role of FECH in different cells and its expression under pathological conditions.  
6.7.1. Understanding the role of FECH in angiogenesis 
Using an siRNA based approach combined with immunoblot technique I 
showed that FECH knock down decreased levels of eNOS. This is used as a 
basis to rationalize that HIF-1α levels are decreased, as eNOS is responsible for 
the stability of HIF-1α under normoxia (Mateo et al., 2003; Olson and van der 
Vliet, 2011; Palmer et al., 2000). However it would be good to show this 
decrease in HIF-1α in other secondary assays such as luciferase reporter assays 
wherein we can monitor the transcriptional activity of HIF-1α after FECH knock 
down. Also, it needs to be tested if exogenous addition of NO donors will rescue 
HIF-1α levels in FECH knock down HRECs. These experiments will confirm if 
FECH regulates HIF-1α levels through eNOS. Also it would be interesting to 
study the effect of overexpression of HIF-1α in FECH knock down HRECs on the 
angiogenic abilities of HRECs.  
 Decreased HIF-1α results in VEGFR-2 reduction in HRECs (Forsythe et 
al., 1996). However, it would be interesting to know if HIF-1α levels are 
decreased under hypoxia when FECH is knocked down, as HIF-1α stability is 
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increased because of reduced activities of PHDs and VHL. This would suggest if 
there are additional mechanisms through which FECH exerts its angiogenic 
activities. Also, it would be interesting to delineate if reduction in VEGFR2 is the 
direct result of decreased HIF-1α or decreased VEGF production. HIF-1α is 
responsible for transcription of VEGF gene (Minchenko et al., 1994) and the 
VEGF in turn stimulates production of VEGFR2 (Guangqi et al., 2012). 
6.7.2. FECH functions in endothelial and non-endothelial cells 
To date, there is no satisfactory explanation for why 5-ALA administration 
results in accumulation of porphyrins in endothelial cells and actively growing 
cancer cells (Dailey et al., 2000; Inoue et al., 2013). Being an inducer of heme 
biosynthesis, 5-ALA should have resulted in accumulation of heme or its 
degradation products such as biliverdin. This suggests that there are additional 
regulation mechanisms controlling activity of FECH in endothelial cells. It will be 
interesting to know these control mechanisms and FECH interacting proteins. 
Identification of FECH interacting proteins both in HRECs as well as non-
endothelial ocular cells will help explain why FECH inhibition specifically affects 
HRECs. Also, identifying other heme-binding proteins which are specifically 
affected by FECH knock down will give us some clues to the role of these 
hemoproteins in ocular angiogenesis. This will broaden our knowledge about 
angiogenesis and open new ways to target angiogenesis specifically.  
Also, IHC experiments showed that FECH is upregulated throughout the 
retina and choroid in wet AMD patients. This corroborates the reports that FECH 
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expression is induced by hypoxia as choroidal neovascularization in patients is 
associated with hypoxia. As hypoxia upregulates FECH expression throughout 
the retina and choroid, it is imperative to understand what are the factors that 
make retinal endothelial cells specifically vulnerable to FECH inhibition. Hence 
understanding the FECH interacting partners in both retinal endothelial as well as 
non-endothelial cells provide the clue for this selected vulnerability and also 
opens up potential angiogenic pathways in which FECH could participate.  
6.7.3. Study of CNV and RNV in FECH mutant mice 
There are two different mouse models for EPP. Both of these models have 
a mutated Fech gene, and as a result have decreased Fech activity. One of the 
mouse models, the Fechm1Pas mouse, was generated by chemical mutagenesis 
wherein a missense mutation (M98K) causes less than 10 % residual activity in a 
homozygous mouse (Boulechfar et al., 1993). However a heterozygous mouse 
shows 45-65 % of normal FECH activity. In the other mouse model, exon 10 of 
the Fech gene is deleted and 50 % residual enzyme activity is observed in a 
heterozygous mouse (Magness and Brenner, 1999). While homozygous 
Fechm1Pas display protoporphyria, heterozygous mice have a normal phenotype.  
Subjecting these mouse models to OIR and L-CNV and studying 
neovascularization in these models will confirm the role of FECH in ocular 
diseases arising from pathological angiogenesis. This will also help understand 
the molecular mechanism by which FECH exerts its angiogenic activity. 
Measurement of the levels of eNOS, HIF-1α and VEGFR2 in these mice under 
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ischemic conditions will help us to confirm in vitro results and pave the way for 
further elucidation of the mechanism. 
6.7.4 Therapeutic potential of FECH inhibitors 
We have shown that FECH is crucial for ocular neovascularization and 
inhibitors of FECH could be developed to specifically target CNV and RNV. This 
work reveals three potential molecules for drug development: cremastranone, 
SH-11037 and griseofulvin. 
Cremastranone isolated from extracts of Cremastra appendiculata has 
been in tested by others in both L-CNV and OIR mouse models for its 
antiangiogenic activity and toxicity (Kim et al., 2007; Kim et al., 2008). It inhibited 
ocular neovascularization in both the mouse models. Considering its high 
potency and less toxic effects on other cell lines, cremastranone might be 
developed as a drug to treat ocular diseases such as wet AMD, PDR and ROP. 
In addition I established SAR for cremastranone along with identification of the 
more potent compound, SH-11037.  Similarly, compound SH-11037 has also 
been tested in the OIR mouse model and shown to inhibit retinal 
neovascularization with high potency. The high potency and selectivity against 
HRECs make SH-11037 a particularly appealing lead molecule for drug 
discovery. However there are still many pharmacokinetic and pharmacodynamic 
properties of cremastranone and SH-11037 that need to be established. As both 
cremastranone and SH-11037 are small molecules, formulating them as eye 
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drops for treatment would be another possible advantage as a therapy for 
patients who receive intraocular injection of biologic drugs. 
Another important observation from this work is that griseofulvin, an 
antifungal drug with an off-target effect of inhibiting the mammalian FECH activity 
(Brady and Lock, 1992; Epstein et al., 1972), blocks ocular neovascularization in 
the L-CNV model when administered orally and also through intraocular injection. 
Griseofulvin is an orally administered drug and has very well established 
pharmacokinetic and pharmacodynamic properties. Its presence in the market for 
several decades without any major toxicity issues make it an appealing drug for 
immediate testing in human clinical trials.  
6.8. CONCLUSION 
Altogether, this research work has encompassed a variety of drug 
discovery initiatives such as cremastranone target identification, target validation 
of FECH, establishing SAR of a lead molecule (SH-11037) and testing in 
preclinical models along with supporting data for repurposing of griseofulvin for 
treating ocular diseases arising from pathological angiogenesis. This work has 
revealed FECH as a novel mediator of ocular angiogenesis along with profiling of 
three small molecules as either lead molecules or drugs for treating ROP, PDR 
and wet AMD. The hope is that this discovery will help further understanding of 
the role of FECH in angiogenesis. The greater anticipation from this work is that 
one day this work may lead to successful new drugs for treating ROP, PDR and 
wet AMD. 
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